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Abstract
Long-term, persistent infection with high-risk strains of human papillomavirus (HPV)
is the precursor of most cervical cancers and an increasing number of the head and neck
cancers. While HPV vaccines can protect patients under twenty-five years old from
possible infections, no HPV antiviral drugs are available for the definitive treatment of
preexisting or future viral infections. To treat current or future HPV infections, drugs that
selectively block virus-specific processes, but do not damage the host cells, are needed.
The compounds developed in our group are unique Imidazole-pyrrole polyamides,
analogs of natural products Distamycin A and Netropsin that function by interfering with
natural virus-host interactions.
Within the overall program of my group, my work focuses on three specific projects.
The first project (Chapter 2) includes bioavailability LC-MS/MS analysis study of one of
the leading compounds in plasma and whole blood.
The second project includes the biophysical study of interactions between two
polyamides, called TMG Asymmetric Hairpin Polyamides (TMG-AHP), and an essential
viral DNA segment. The aim of this study was to determine where and how strongly the
compounds bind to the viral DNA. In this work, two methods were used: the quantitative
deoxyribonuclease (DNase I) footprinting method and the affinity cleavage assay (AC).
The results are presented in Chapters 3 and 4. The remarkable findings resulted in binding
location maps that help us to better understand the mechanism of action of AHPs and to
address the question: what is the primary reason for neutralizing a virus by our
polyamides.
Based on the knowledge gathered from the results of the second project, a complex
study (RNA-Seq) concerned with genome expression was performed. The aim of the third
project is to find the common features and differences in the polyamides’ mechanism of
action by quantifying messenger RNA (mRNA), after treatment of HPV infected skin cells
with 8 different polyamides.
In parallel with the analysis of human and viral transcriptome, a separate study
concerned with the differential expression profile of seven DDR genes that are
components of the homologous recombination (HR) pathway have been studied by RTqPCR method. The results are presented in Chapter 5 and 6. Data gathered from the third
project helps us further understand the mechanism of polyamide action.
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Chapter 1
Introduction
Human papillomavirus. Polyamides as potential HPV antiviral drugs
1.1 Abstract
Long-term, persistent infection with high-risk strains of human papillomavirus
(HPV) is the precursor of most of the cervical carcinomas (1, 2) and an increasing number
of oropharyngeal squamous cell carcinomas, which represent 90-95% of head and neck
cancers (3). While vaccines can protect the approved population from possible infections
(4), no HPV antiviral drugs are available for the definitive treatment of preexisting or future
viral infections. The approved population has a complex definition given the existence of
a bivalent vaccine (for HPV16 and 18), a quadrivalent vaccine (for HPV6, 11, 16, and 18)
and a recent nonavalent vaccine), but is generally stated as “boys and girls from ages 1113” to “men and women through age 26” (http://www.cdc.gov/std/hpv/stdfact-hpv-vaccinehcp.htm). To treat current or future HPV infections, drugs that selectively block virusspecific processes, but do not damage the host, are needed.
The compounds developed by our group are unique imidazole-pyrrole polyamides
(PA), analogs of the natural products Distamycin A and Netropsin that function by inducing
parts of the DNA Damage Response (DDR) (5, 6) and perhaps by interfering with natural
virus-host interactions. Note that when this thesis project was started, no information about
the DDR had yet been understood in a mechanistic sense and all focus was still on moretraditional, sequence-specific DNA recognition rules for biologically-active polyamides.
Within the overall program of my group, my work focuses on three specific projects.
The first project (Chapter 2) includes a bioavailability LC-MS analysis study of one of the
leading compounds PA25 (NV1042) in plasma and whole blood.
The second project includes the biophysical study of interactions between two
polyamides, called TMG Asymmetric Hairpin Polyamides (TMG-AHP), and an essential
viral DNA segment. The aim of this study was to determine where and how strongly the
compounds bind to the viral DNA. In this work, two methods were used: the quantitative
deoxyribonuclease I (DNase I) footprinting method and the affinity cleavage assay (AC).
The results are presented in Chapters 3 and 4. The remarkable findings resulted in
binding-location maps that help to better understand the mechanism of action of AHPs
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and to address the question: “What is the primary reason for neutralizing a virus by our
polyamides?”
Based on the knowledge gathered from published reports on gene expression with
subsets of genes (7-9), the results of parallel studies with more-traditional but long,
antiviral polyamides from our group (5, 6), and the second project (Chapters 3 and 4), the
third project was devised, and a complex study (RNA-Seq) concerned with genome-wide
gene expression, at the mRNA level, was performed. The aim of the third project was to
find the common features and differences in the polyamides’ mechanism of action by
quantifying messenger RNA (mRNA), i.e. determining gene expression, after treatment of
HPV-infected skin cells with 8 different polyamides. In parallel with analysis of the human
and viral transcriptome, a separate study concerned with the differential expression profile
of seven DDR genes that are components of the homologous recombination (HR) pathway
were studied by quantitative PCR, or the qPCR method. The results are presented in
Chapters 5 and 6. Data gathered from the third project helped us further understand the
mechanism of polyamide action so we may further develop future antiviral compounds to
prevent cervical cancer and other HPV-derived diseases.
Our group’s collaboration with NanoVir led to the discovery of compounds useful for
eliminating HPV, unique large polyamides which decrease the amount of HPV DNA in
infected cells and tissue and have great potential as possible drugs for the treatment of
HPV infections (5, 6, 10-12). Biophysical results helped lead to further antiviral discoveries
with new viruses, the polyomaviruses (U.S. Patent Appln. 14/818881, JK Bashkin, TG
Edwards, C Fisher, GD Harris Jr, KJ Koeller, Antiviral compounds and methods for treating
infections caused by double-stranded DNA viruses, 2015/11/19).
1.2 Human papillomavirus (HPV)
Human papillomaviruses (HPVs) are small dsDNA viruses which belong to the
large family Papillomaviridae, a group of viruses that infect the stratified epithelia,
keratinocytes, of the skin and mucous membranes. More than 140 types of human
papillomaviruses have been fully sequenced and they are grouped by sequence homology
into five genera. The high-risk HPV16, HPV18, and HPV31 are part of the alpha genus
(13). Human papillomavirus possess a circular genome (HPV16 being 7904 base pairs
long) that typically contains 8 genes. Genes and proteins of HPV are named according to
timelines for viral gene expression as either early (E1, E2, E5, E6, E7) or late (L1, L2, and
E4) (13-15). E1, E2, E4, E5, E6, and E7 are nonstructural proteins, while L1 and L2 are
2

structural proteins. The nucleotide sequence of L1, one of the late genes encoded by virus
DNA, constitutes a basis for HPV classification. The different HPV types are divided into
those preferentially infecting the skin versus those infecting mucosal surfaces (16).
Among the mucosal HPVs, at least 15 types are considered high-risk (16), with
HPV 16 and 18 accountable for >70% of HPV-induced cancers in the US (17). Cervical
cancer is the second largest cause of cancer deaths in women worldwide (2).
Approximately 11,000 women are diagnosed with cervical cancer in the USA annually and
a third die of this disease (17). The high-risk HPVs are associated with cervical cancer
and also with many penile, vulvar and anal carcinomas, and contribute to over 40% of oral
cancers (1, 18).
For the discovery that high-risk HPVs cause cervical cancer, Harald zur Hausen was
awarded Nobel Prize in 2008, cementing the importance of knowledge related to HPV
(https://www.nobelprize.org/nobel_prizes/medicine/laureates/2008/hausen_lecture.pdf).
Both prior and subsequent to this, many studies have been published concerned with the
HPV-induced carcinogenesis, which is still not completely understood (1, 16, 19).
However, it is well-established that malignant transformation (16) is related to the
persistent overexpression of HPV E6 and E7, the oncogenic proteins (15, 16, 20).
Only a few HPVs are oncogenic, however, from which we infer that the protein
activities of high-risk HPVs are different in a few aspects from the corresponding protein
activities of HPVs associated with benign diseases, with limited oncogenic potential (20).
Although the relative oncogenicity of E6 vary depending upon the HPV type, there is
important overlap in the pathways altered by low- and high-risk HPV E7 (20). Carcinomas
occur in the transformation zone of the cervix where the columnar and squamous epithelia
meet (20). The intracellular milieu of the basal cells in this region may limit the completion
of the productive life cycle (20, 21): therefore, if the productive life cycle cannot be
completed (20), then no virions can be formed and the transformation of the cells might
be favored.
The integration of the viral genome into the genome of the host cell is common;
it is not a necessary pre-requisite for the development of cancerous tumors. HPV 16, 18
and 45 are more frequently found in an integrated state than HPV 31 and 33 (22). When
integration of the viral DNA into the host’s chromosomal DNA occurs, no virions are
produced. HPV integration usually occurs near or within known fragile sites (5) and often
disrupts E2 expression (15). E2 autoregulates its own expression and regulates
expression of E6 and E7. Disruption of E2 results in increased levels of expression of E6
3

and E7 which then induce the formation of tumors. A second path for malignant
transformation could occur in cells that maintain viral episomes (1), and the expression of
E5 would increase the activity of E6 and E7, leading to subsequent tumor progression (1).
The E6 and E7 proteins provide functions necessary for the differentiationdependent life cycle of HPVs in addition to their roles in immortalization. These two HPV
proteins also play critical roles in modulating immune evasion. Expression of E6 and E7
oncogenes is regulated on the transcriptional level (23) in the viral long control region
(LCR) (23), which is well-conserved in different HPV16 isolates (24).
E7 proteins do not possess intrinsic enzymatic or DNA-binding activities but
function by binding to several cellular factors (1) such as the Retinoblastoma tumor
suppressor (pRb). pRb which normally prevents cell growth by inhibiting cell cycle
progression is destabilized by E7. E7 protein propagate immortalization through
interaction with proteins that control cell cycle progression (1). E7 proteins also target
members of the interferon pathway (1). Interferons trigger the protective defenses of the
immune system in response to the presence of viruses. The efficient binding of E7 to Rb
family members and other cell cycle regulator proteins also results in the increase in the
levels of the tumor suppressor p53, which limits cellular growth and increases the
susceptibility of E7-expressing cells to apoptosis (1, 25).
To diminish increased levels of p53, high-risk E6 proteins use several
mechanisms to interfere with p53 functions (1), such as the formation of an E6–E6associated protein (E6AP)–p53 (1); formation of the trimeric complex results in p53
degradation (1). Also, the interaction of E6 with the histone acetyltransferases prevents
p53 acetylation, inhibiting the transcription of p53-responsive genes (1). High-risk E6
proteins also activate transcription of telomerase reverse transcriptase (TERT), another
essential step in immortalization (24, 25). E6 also interacts directly with components of the
IFN response (1, 26).
The expression of E6 and E7 is necessary but not sufficient for malignant
progression (1). In the amplification phase of the HPV life cycle (see HPV lifecycle below),
E6 and E7 promote the proliferation of undifferentiated and differentiated cells, in the same
time allowing the avoidance of apoptosis (1). This phenomenon leads to an accumulation
of DNA damage and genomic mutations (1).
E5 protein can augment the function of E6 and E7 and contribute to tumor
progression (1). E5 proteins are small, hydrophobic polypeptides approximately 83 amino
acids in size that localize primarily to the endoplasmic reticulum (1).
4

1.2.1 The HPV lifecycle
Three major phases in the HPV lifecycle can be detected (1) the initial
amplification post infection (2) the non-productive or maintenance phase and (3) the
productive phase, or amplification phase (Figure 1.1).
All HPVs infect the basal cells of stratified squamous epithelia via micro abrasions
(20) . Basal cells are undifferentiated skin cells and are the only proliferating (dividing)
cells in normal epithelia (1). HPV virions infect the basal layer via heparan sulfate
proteoglycans and integrin proteins (27). Integrin proteins are upregulated during wound
healing and have been reported to play a role in viral attachment and entry. After being
taken up, the viral particles travel to the nuclear membrane by the endosomal pathway
(28), where the major and minor capsid proteins (L1 and L2) are left behind and the viral
genome in the form of a chromatinized double-stranded DNA circular episome is
transported into the host cell nucleus (27). After membrane penetration of mitotic cells and
nuclear import, the virus locates to nuclear bodies, or nuclear domains, known as ND10
(28). It was proposed that ND10 bodies are associated with regions of DNA damage in
uninfected cells (8). In the basal cells, the viral genome is maintained extrachromosomally
(20) as episomes that can be replicated independently from the host chromosomal DNA.
In the initial amplification stage, the viral genome replicates but maintains a low
copy number as a consequence of the expression of the E8^E2 transcript which is the
repressor of viral transcription and replication (29-31). To produce a persistent infection,
the virus has to be able to evade immune responses. HPV is effective at evading
immunological detection and produces only a slow and weak immune response which
varies among patients (32). Not just in the initial amplification stage but during the whole
lifecycle of HPV, the exposure to the host immune system is limited. Infections do not
produce viremia, the presence of viruses in the blood, and a limited load of antigenic HPV
proteins is produced as a result (4).
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Figure 1.1. Episome copy numbers in different phases of replication. Adapted from (8)

The maintenance phase is the phase in which the episomal DNA is maintained at
a few hundred copies of episomes per cell and no viral structural proteins are produced
(15, 20). The W12E cervical keratinocyte cells were purified from a clinical isolate and are
undifferentiated cells which harbor 100-500 viral episomes per cell (5, 6, 10). These cells,
which mimic cells harboring viral episomes in the maintenance phase, were used as the
model for the gene expression studies. They were a kind gift of Dr. Paul Lambert of the
Medical School at The University of Wisconsin, Madison.
To transition or progress to the maintenance phase, the viral genome has to be
tethered to beneficial regions of chromatin and to modulate DDR responses. In the
maintenance phase, depending on the HPV type, replication of the episomes occurs
during S-phase along with the host genome, or by a random choice mechanism (33). High
levels of E1 promote mostly random choice replication in W12 cells (33) and trigger a DDR
response imposed by ATM (34) to ensure replication of the virus. In the S-phase, the
episome is (or may be, see later discussion) attached to the host chromatin using E2 as
an intermediate. E2 binds the episome on its DNA binding domain and also binds the
BRD4.
The BRD4 tethers the episomes to the host chromatin (at fragile sites as
demonstrated in C-33 cells (35)) to ensure replication. BRD4 is important for genome
tethering during maintenance and as well as a viral replication center initiator present in
the amplification phase (8, 36). This tethering mechanism ensures that the low copy of the
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viral genome is retained in the nucleus and is distributed to daughter cells (36). The
binding model for HPV18 is shown in Figure 1.2.

Figure 1.2. Model of E2-mediated Tethering of the Viral Genome to Host Chromatin (36) The DNAbinding domain is of the HPV18 DNA binding domain bound to DNA (shown in light purple) from
the PBD file 1JJ4 (36).

Binding of E2 to Brd4 is not sufficient for tethering the viral episome to the mitotic
chromosome; E2 also has to bind ChIRI (37, 38). Recently the HPV16-BRD4 complex
was analyzed by bimolecular fluorescence complementation experiments (8, 39) and with
the help of experiments where E2 is expressed as a GFP-fusion protein (40). Many studies
concerned with the role of BRD4 as a key regulator of transcription also found that BDR4
may be associated with DDR elements and also associates with fragile sites (35). BDR4
is an insulator chromatin that can modulate the signal of DNA damage (41).
However, new studies display a model in which the viral episomes (HPV 31) bind
to the host chromatin in a way that is independent of BRD4 protein (42). This controversy
has not been resolved and is complicated by the fact that the majority of studies on BRD4
were done with chimeric human/bovine papillomavirus systems and/or with E2 highly
overexpressed.
Viral replication centers are distinct nuclear foci that contain recruited nuclear
replication factors associated with the host DDR; with the help of which viral genomes are
replicated. Replication foci can be detected in differentiated cells (8). BRD4 is initially part
of the replication process by concentrating viral proteins in specific regions of host
chromatin (43). It was shown that DDR factors are present in the replication centers in the
case of differentiated keratinocytes (19).
In the amplification stage of the viral life cycle, a rapid increase of viral DNA and
virion production also occurs (8, 20). The synthesis of virions, or viral particles, that are
able to shed and infect other organisms occurs only after cells have differentiated,
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migrating towards the outer layer of the epithelium (15, 20). For virion production, the late
genes L1 and L2, which code for capsid proteins, must be expressed (16). The genome
amplification in this stage is thought to be a rolling cycle type and may be linked to DDR
(9). Recent findings identified SMC1 (cohesin protein) and CTCF (insulator transcription
factor) as critical regulators of differentiated high-risk human papillomaviruses (42).
Viral gene expression is controlled through two viral promoters. The early
promoter (p97 for HPV 16, Fig.1.3) is located in the upstream regulatory region (URR) (8)
adjacent to the E6 open reading frame (ORF) and is active in the infection process and
during the maintenance phase (44). Promoter p97 directs expression of the E1 and E2
replication proteins (8), which leads to the establishment of viral genomes, as well as the
expression of the viral oncoproteins E6 and E7 which regulate cell cycle progression.
Transcription stops at the early polyadenylation (poly(A)) site AE and the transcript is
processed by using the early splicing signals (45).
As HPV-infected cells differentiate, the late HPV promoter p670 (Figure 1.3)
located in the middle of the E7 ORF is activated (44), leading to expression of late gene
products such as E4, L1, and L2, and increased levels of E1 and E2 (15, 46). In
differentiated cells, the transcripts expressed from the late promoter utilize a late poly(A)
signal, AL, and late splicing signals (45). The early and late splicing signals compete for
the splicing factors, so their usages are exclusive (45).

Figure 1.3. The HPV circular dsDNA genome structure. Viral genes are transcribed in clockwise
direction. The LCR contains a DNA replication origin and functions as a regulator for DNA
replication (45, 46).
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1.2.2 The DDR’s role in viral episome maintenance (Chapter 5)
In general, infection by DNA viruses induces the activation of many cellular pathways,
including those involving p53, stress, apoptosis and the DNA damage response (DDR)
(7). The DDR can detect foreign DNA and can also sense aberrant DNA structures that
form as a result of chromatin changes during nucleic acid transactions such as
transcription and replication (47). DDR response is also triggered by changes in chromatin
structure (35).
The presence of HPV’s circular dsDNA episomes initiates a DDR response. The HPV,
a small virus, which contains no polymerase, just two replication proteins (E1 and E2)
employs some of the DDR elements for its replication.
In Figure 1.4 the DDR to single stranded and double-stranded breaks is described
(48).

Figure 1.4. DNA damage response to single-stranded and double-stranded breaks (48). ATM:
Ataxia-telangiectasia mutated kinase; ATR: Ataxia-telangiectasia and RAD3-related kinase;
ATRIP: Ataxia-telangiectasia and RAD3-related kinase-interacting protein; RPA: Replication
protein A; TOPBP: Topoisomerase binding protein.

RPA coats single-stranded DNA and is subsequently recognized by an ATRATRIP complex (48). The RAD9-RAD1-HUS1 (9-1-1) complex binds to the 5′ overhang
near the exposed ssDNA and brings in TOPBP1 which activates ATR in the presence of
ATRIP (48). ATR phosphorylates many downstream targets including Chk1, the cell cycle
checkpoint kinase, and p53 (48). When Chk1 is phosphorylated, it will arrest the cell cycle
(34).
Double-stranded DNA breaks are detected by the Mre11–Rad50–Nbs1 complex,
which promotes monomerization and autophosphorylation (activation) of the ATM kinase
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(48). Activated ATM will lead to phosphorylation and activation of its downstream effector,
Chk2 kinase, and p53, H2AX (γH2AX) and Nbs1, among many more targets (48).
The ATM pathway activated by ds-breaks and the ATR pathway activated by
single-strand breaks were thought to function in parallel. However, recent studies
reviewed by Hong and Laimins (15) indicate that these two pathways are linked to each
other. ATR seems to be subordinated to elements of ATM. The ATR–CHK1 pathway
requires activation by ATM. ATR is sensitive to radiation-induced ds-breaks and the
MRE11/RAD50/NBS1 (MRN) complex that induces autophosphorylation of ATM is also
needed for ATR activation (15).
The present study will involve W12E cells, undifferentiated keratinocytes which
maintain the episomal high-risk HPV16 genome. Four viral proteins, E1, E2, E6, and E7,
are required for the maintenance of viral DNA in cell cultures (45). The capsid proteins L1
and L2, essential for the infectious particle (virion) formation, are not expressed in
sufficiently high levels in the undifferentiated cells that will be used.
1.3 Polyamides as potential HPV antiviral drugs
N-methylpyrrole-N-methylimidazole polyamides (PA) are versatile homologs of the
naturally occurring antibiotics Distamycin A and Netropsin, small, crescent shaped
polypyrrole peptides that bind to repeating A/T tracts (49) in minor grooves with modest
affinity and specificity (49-51). Distamycin has antitumor and antiviral proprieties but also
a high toxicity (10, 49, 52).
To overcome the high toxicity but maintain antitumor and antiviral properties,
polyamides were designed following the Distamycin model. By introduction of imidazole
(Im) building blocks, recognition of G and tracks that include G became possible, leading
to reported pairing rules (53, 54) pyrrole (Py) binds to the three nucleotides which present
H-bound acceptors in the minor groove A, T, and C. γ-turn, γ-aminobutyric acid binds to
A/T or T/A nucleotides. The cationic tail (Ta) aids binding and recognizes A/T or T/A
nucleotides; β-alanine (β-spring) binds to A, T or C. Then β-alanine units confer additional
flexibility and better follow the DNA curvature (54, 55). The flexibility of the β units can
help optimize the interactions of polyamides with the targeted DNA bases, however, the
number and position of the substitutions influence the binding affinity of polyamides in the
minor groove of DNA, though this level of sophistication was ignored in the original
literature but was recently reported (56-58). Polyamides specifically recognize and bind
with high affinity to dsDNA in minor groove regions by hydrogen-bonds (49, 59).
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The binding of PAs is followed by alterations of the dsDNA shape by widening the
minor grove, narrowing the major groove (54, 60), and stiffening the double helix (61).
By binding with high affinity in the minor groove, the small polyamide molecules
can fulfill different functions such as the regulation of gene expression, or the molecules
may be used as molecular probes. Polyamides are able to displace many proteins from
DNA interfering with gene expression at transcription levels (62). Also, PAs can be
specifically designed to bind to recognition sites of the transcription factors (49, 63) of
dsDNA, silencing aberrant gene expression or infectious diseases in this way. A strategy
of suppressing viral DNA transcription was successfully employed for destabilizing the
Epstein-Barr virus (64).
Conjugated polyamides can function as site-specific alkylating agents able to
covalently modify DNA (49). Alkylated DNA can mimic methylated DNA, interrupting
transcription and selectively silencing targeted genes (49). A possible chemotherapeutic
choice for cancer treatment is the use of polyamide-alkylator conjugates to silence the
oncogenes (49, 65). Bifunctional PAs could also be used to alkylate human telomeres
(1000 or more tandem repeats of a short G-rich sequence, TTAGGG, on the 3’ end of
each chromosome (66) ) and abrogate the increased telomerase activity of cancer cells
(49, 67). Polyamide-peptide conjugates can function as synthetic transcriptional activators
as well (49). Recent work showed the results of coupling a hairpin polyamide to a
suberoylanilide hydroxamic acid (SAHA) moiety (68), known to act as a histone
deacetylase inhibitor with broad epigenetic activity (49). Histone acetylation will loosen up
the nucleosome, allowing the genes to be expressed (68, 69).
Polyamides are also used as molecular probes. When PAs bind to dsDNA match
sites, the fluorescent signal produced by the polyamide-fluorescent dye conjugates is
enhanced, allowing them to be used in cellular localization studies (70). Although the
fluorescent dye used in imaging experiments can affect the cellular uptake of PAs, many
studies (59, 71, 72) provide significant results to provide evidence that PA uptake is
achievable over a wide range of PA molecular weight (up to 4000 Da) and cell types (73).
PAs accumulate within cells by either passive diffusion, regardless of their
molecular size (73, 74), or active diffusion, which is energy-dependent, such as in the case
of HeLa cells (74). Effective cellular uptake of PAs was also observed in a range of human
primary keratinocytes, including keratinocytes harboring HPV infections (5, 10). Therefore,
the process of PA uptake into cells is extremely well studied. Efficient PA uptake was also
exhibited in some animal studies (71, 75). Molecular size does not influence the cellular
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uptake (polyamides can cross plasma membranes) (73). However, the permeability of the
nuclear membrane is sometimes reduced for larger polyamides (73). Many studies show
that PA uptake in cells is achievable, but varies with cell line and PA structure (imidazole
content, structure of the “tail”, hydrophobic qualities, β-alanine (57), and gamma turns (54,
71, 74)). According to cell and animal studies, some polyamides have cytotoxic effects
(76-78), while others, such as the case of anti-HPV polyamides that decrease viral DNA
levels, exert their effects without toxicity. Sometimes, efficiency is diminished or impaired
because polyamides are not able to reach the target destination, the nucleus of the cells.
Quantitative measurements have shown that the concentration in the nucleus of
polyamide–fluorescein conjugates is lower than the media concentration and differs
according to the cell line (75). Accumulation of polyamides in the cytoplasm (79) and
sequestration in acidic vesicles was evidenced by confocal laser scanning microscopy
and flow cytometry measurements (73). Multidrug resistance (MDR) causes polyamides
to be stored in acidic vesicle in some transformed cells; nevertheless, uptake can be
improved using inhibitors of MDR (70)
Earlier studies show that much of the DNA in the nucleosome (the elemental
repeating unit of all eukaryotic chromatin (80), consisting of histone proteins around which
146 bp of DNA are wrapped (80)) is freely accessible for polyamide binding in the minor
groove (54, 81). The sites on nucleosomal DNA facing away from the histone octamer and
the sites partially facing the histone octamer are fully accessible for DNA binding (80)
(PDB: 1M18, 1M19, 1M1A). Polyamides not bind where sites are completely blocked by
interactions with the histone octamer (81). The structure of the histone octamer and its
interaction with the DNA is unaffected by PA binding (80). However, the nucleosomal DNA
undergoes structural changes at PA binding sites and the adjacent regions, such as the
widening of the minor groove and alterations of the DNA twist angles, which are
propagated to distant regions (80). The details of the changes upon PA binding are
revealed by the crystal structures of the nucleosome (80). The study also suggested that
nucleosome-bound DNA is capable of adjusting its structure to allow binding.
In vivo studies suggest that polyamides have an unexplained preference for some
nucleosomal DNA binding positions. Research done in Dervan’s lab revealed that a
polyamide-DNA alkylator, chlorambucil, with high affinity, binds solely to two of the perfect
matching sites of the H4C (highly expressed histone protein in cancer cells) gene. No
other gene downregulation (a consequence of the polyamide binding) was observed, even
if possible binding sites of this polyamide are present many times in the human genome
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(77). The binding of the polyamide to the H4C gene in colon cells may be caused by
differences in nucleosome placing or nuclear localization of PA (59, 74, 77). Other studies
focusing on nuclear chromatin access by a polyamide-chlorambucil conjugate showed that
PA binding was restricted to a limited number of genes (82).
In conclusion, even though nucleosomal DNA is partially accessible for high-affinity
binding, in vivo studies show that the binding patterns of PA to a certain cell type genome
are not completely predictable. Comprehensive binding studies are required to understand
the complex, dynamic processes that take place in the cells.
A special class of polyamides and potential drug candidates, long Nmethylpyrrole-N-methylimidazole hairpin polyamides, were synthesized in Dr. Bashkin’s
lab using Boc-chemistry solid phase synthesis procedure (83-85). These polyamides were
found to have anti-HPV activity against three different HPV genotypes: HPV16, 18, and
31 (5, 10, 26). Binding in the minor groove of dsDNA (54, 57, 60) causes structural
alterations of supercoiled dsDNA, perhaps causing ssDNA exposure or double strand
breaks (DSBs) within HPV episomes, but in any case resulting in the activation of DNA
damage response (DDR) pathways (6). Activation of DDR genes eliminates (causes
enzymatic destruction of) viral episomes without having significant effects upon cell growth
or apoptosis (6). These special polyamides have the ability to decrease HPV16 episome
levels in undifferentiated W12E cell monolayers and tissue culture in the absence of
integration of viral DNA.
In the present study, a new class of derivatives of antiviral polyamide NV1042, also
called PA25, was used. These compounds have a modified N-terminal capping group,
1,1,3,3 tetramethylguanidine (TMG) or guanidine at the N-terminus. Previous work results
(NanoVir, LLC, Table 1.1 and 1.2) demonstrated the antiviral activity of the compounds
by attesting the decrease of HPV DNA levels in human keratinocytes by more than 90%
in

cells

that

maintain

HPV16,

HPV18,

or

HPV31

DNA.

Moreover,

the

tetramethylguanidines (TMG) displayed as much as a 5-fold greater efficiency in human
keratinocyte cell culture against HPV16, 18 and 31 than the best dIm-terminated members
of the library on which they were based.
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Table 1.1. Polyamides used in the following studies. The IC50 and IC90 values measured for W12E
cells were determined by T. G. Edwards in the Fisher lab, unpublished data.

Poyamide (PA)
NV1011 (PA11)
NV1028 (PA1)
NV1042 (PA25)
NV1078
NV1087
NV1111
NV1113
NV1115

HPV16 IC50
[µM]
NOT ACTIVE
0.100
0.036
0.046
0.031
0.017
0.304
0.103

HPV16 IC90
[µM]
NOT ACTIVE
1.113
0.351
0.307
0.200
0.121
>10
0.378

HPV18 IC50
[µM]
NOT ACTIVE
0.717
0.056
0.030
0.024
0.018
0.228
0.167

HPV18 IC90
[µM]
NOT ACTIVE
>10
1.462
0.091
0.297
0.136
>10
0.937

Table 1.2. Sequences of polyamides (PAs). PA1 and PA25 are the original preclinical lead
compounds. Abbreviations: Im represents N-methylimidazole, Py is N-methylpyrrole, β is β–
alanine, γ is γ-aminobutyric acid, and Ta is CH3N(CH2CH2CH2NH2)2 or 3,3’-diamino-Nmethyldipropylamine. The polyamides were synthesized by solid phase synthesis as previously
described (10, 26).

Polyamide (PA)

PA sequence

N-terminal group

NV1011 (PA11)

ImPPIm-γ-PPPPβDp

Im

NV1028 (PA1)

ImPPβPPP-γ-PPβPPPPβTa

Im

NV1042 (PA25)

ImPPβPPImβPP-γ-PPβPPPβPPPβTa

Im

NV1078

TMG-PβPPImβPP-γ-PPβPPPβPPPβTa

TMG

NV1087

TMG-PPPβPPβPIm-γ-PβPPβPPPβPβTa

TMG

NV1111

Guan-PPPβPPβPIm-γ-PβPPβPPPβPβTa

Guan

NV1113

TMG-ImPPβPPP-γ-PPβPPPPβTa

TMG

NV1115

Guan-ImPPβPPP-γ-PPβPPPPβTa

Guan
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Chapter 2
Polyamide Bioavailability
Analytical Studies of Polyamide Content in Plasma and whole Blood
2.1 Introduction
This chapter includes the LC-MS analysis of different blood fractions provided by
MPI RESEARCH (2026-006) and whole blood analysis of K2EDTA-treated rat blood
(Fisher Scientific). Prior to this study, animal studies (MPI 2026-003) were conducted by
WIL Research Laboratories, LLC, 1407 George Road, Ashland, OH 44805-8946, using
an analytical method developed by MPI Research, a subsidiary of WIL Research, and
qualified under MPI Research Study Number 2026-001.The project was approved by NIH
and animal safety was approved by the Institutional Animal Care and Use Committee
(IACUC) established by WIL labs.
Polyamide (NV1042) was administrated to female Sprague Dawley (SD) rats to
characterize its pharmacokinetic properties, acute and subacute toxicity, estimate the
maximum tolerated dose (MTD), and evaluate the toxicokinetics of the polyamide in the
female rats. The MTD is a dose that does not produce mortality, more than a 10%
decrement in body weight, or significant clinical signs of toxicity.
Since the absorption following topical application (intra-vaginally), the intended
route of clinical administration, was apparently insufficient and special formulations for oral
bioavailability were not available, the intravenous route was selected for drug
administration in order to determine the NV1042 concentration in blood compartments.
This method was thought to be the only alternative to achieve toxicologically-relevant
systemic plasma concentrations. (MPI 2026-002, 2026-003).
NV1042 polyamide was administered by a slow (60 + 5 s) intravenous injection
(IV) at 1, 2, or 5 mg/kg doses. A detailed protocol of the animal studies can be found in
MPI 2026-002 research study, cited above. For plasma analysis, blood samples were
collected in tubes containing K3EDTA as an anticoagulant. The blood samples were
centrifuged and the plasma was stored at -50 to -900C until analyzed.
Polyamide plasma concentration levels were quantified by the LC-MS/MS MPI method
(details in MPI 2026-0010B-01,2 Analytical method). This method was adapted for our
work as described in the paragraph 2.2.6 LC-MS Analytical Method.
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Separate analyses for plasma spiked with polyamide as well as plasma of whole
blood samples extracted from animals after treatment were performed. The results were
different. The polyamide was quantified in plasma samples but not in plasma samples
originating from animals after they received treatment. Plasma concentration levels after
the intravenous administration of polyamide NV1042 were not detected by the MPI
method. (The company claimed that all polyamides were metabolized in the animals.)
Opposing the Contract Research Company’s inference, it was hypothesized that
D5W (5% dextrose, the vehicle used in animal studies) intravenous (IV) solutions
interfered with polyamide analysis and might have caused the polyamide to precipitate
during plasma processing. The differences in the bioavailability of the two situations arises
from the differences between the polyamide sample preparations. In the case when
plasma was spiked with PA, the PA was dissolved in DMSO first and the plasma
concentrations were quantifiable. On the other hand, when PA dissolved in D5W was
injected into the blood stream and analyzed from the subsequently extracted blood
plasma, concentration levels were too low. D5W might have helped absorption, for
example into the cells, though the team leaders did not consider this at the time; they were
more concerned with inappropriate precipitation by the plasma purification procedure.
The purpose of this work was both exploratory and rather desperate: animals had
been sacrificed in the course of carefully designed experiments. Without proof that the
compound was present, the FDA would not accept data from the study to establish a
maximum tolerated dose. This would mean the inacceptable waste of living animals and
the loss of large sums of research dollars and large amounts of test compound prepared
at great expense and effort. If the compound could be found in the samples, as Dr. Bashkin
believed it must be, then large portions of the study would be salvaged in spite of the loss
of pharmacokinetic data.
2.2 Materials and Methods
2.2.1 Polyamide PA25 (NV1042) and Internal Standard NV1057
The polyamide used in the present investigation is one of the leading HPV antiviral
compounds PA25 (NV1042) (5, 10, 12, 86). NV1042 is a large hairpin polyamide with the
following structure: ImPP-β-PPIm-β-PP-γ-PP-β-PPP-β-PPP-β-Ta, where: Im represents
N-methylimidazole, Py is N-methylpyrrole, β is β–alanine, γ is γ-aminobutyric acid, and Ta
is CH3N(CH2CH2CH2NH2)2 or 3,3’-diamino-N-methyldipropylamine (Figure 1). NV1042
was synthesized by solid phase synthesis as previously described (10).
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Figure 2.1. Structure of NV1042. The compound, ImPPβPPImβPPγPPβPPPβTa and the
4 counterions (TFA), has the molecular weight 2982.79
Polyamide NV1042, a member of the programmable heterocyclic oligomers Nmethylpyrrole–imidazole polyamide class of the hairpin type, has a unique importance,
having anti-HPV activity against three different HPV genotypes HPV16, 18, and 31
(Chapter 1, Table 2) (10, 87, 88). The binding of NV1042 by noncovalent bonds in the
minor groove of dsDNA was extensively studied (5, 10, 86). As a consequence of the
binding, structural alterations of superhelical dsDNA cause ssDNA exposure or double
strand breaks (DSBs) within HPV episomes resulting in the activation of DNA damage
response (DDR) pathways (6). Activation of DDR genes eliminate and degrade the viral
episomes without significantly affecting cell growth or apoptosis (6). This special
characteristic made NV1042 an excellent drug candidate to be a subject in the animal
studies.
As internal standard polyamide NV1057(KJK5115) was used.

Figure 2.2. Chemical structure of NV1057 internal standard
Table 2.1. Positive electrospray ionization of the NV1057, the most abundant protonated
ions, generated at 28 eV collision energy are highlighted (data collected on LC-MS/MS
Quadrupole TOF Bruker Maxis, Dr. Bythell’s instrument).
Polyamide Exact mass

[M+H]

NV1057

1885.06 943.03

1884.06

[M+2H]/2
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[M+3H]/3

[2M+H] [2M+3H]/3 [3M+4H]/4

629.02

3769.1

1257.04

1414.045

2.2.2 Plasma and Blood Pellet Provided by MPI Research
Four refrigerated pellets and a total of 8 frozen plasma samples (Analytical method, MPI
RESEARCH, LC-MS/MS analysis for NV1042 in SD Rat K3-EDTA 2026-006) were
received on May 2012 from Christine Wisniewski, MPI Research, Mattawan, MI. The
received samples were processed according to the “Analytical method, MPI RESEARCH,
LC-MS/MS analysis for NV1042 in SD Rat K3 -EDTA 2026-006” protocol. These samples
were collected on 4/27/2012. The summary of the protocol for processing the samples is
provided in the following four paragraphs.
Blood samples (at least 4 mL each) were collected from 3 rats into tubes containing
K3-EDTA anticoagulant. Whole blood samples were transferred (and pooled) into a large
conical tube, inverted gently and equally divided into 2 approximately equal aliquots.
From one aliquot (whole blood), four aliquots (1 mL each) were placed into plastic
tubes and identified as A, B, C, and D. The whole blood samples were spiked with the
polyamide solution to achieve the required concentrations and then spun down to harvest
plasma and the pellets. The collected samples were:
4 plasma samples aliquot A (0 mg/mL PA, received no polyamide treatment), aliquot B
(1000 ng/mL PA), aliquot C (5000 ng/mL PA), and aliquot D (25000 ng/mL PA) and
4 pellet samples: aliquot A (0 mg/mL), aliquot B (1000 ng/mL), aliquot C (5000 ng/mL),
and aliquot D (25000 ng/mL).
The second aliquot was centrifuged at 3000 RPM for 10 minutes at room
temperature. The resulting plasma was extracted and separated in four aliquots (1 mL
each) into plastic tubes. Plasma blood (not whole blood) was spiked to prepare 4 other
plasma aliquots. The aliquots were identified as plasma aliquots AA (0 mg/mL), BB (1000
ng/mL), CC (5000 ng/mL), and DD (25000 ng/mL).
All PA stock solutions were prepared in D5W (5% Dextrose, USP) and added
directly to either the blood or plasma samples. The dose formulations were vortexed for
1-2 minutes, then sonicated until complete dissolution.
2.2.3. Whole Blood
Rat whole blood in K2EDTA (50-412-666) was purchased from Fisher Scientific.
The blood was aseptically drawn from normal healthy animals; but it was not intended for
use in transfusions or other medical applications. The rat blood was stored in the
recommended conditions, 2-8 °C, and remained stable for the purposes of these
experiments for three weeks.
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2.2 4. Plasma Sample Preparation
Plasma samples were prepared for LC-MS analysis by mixing 100 µL of plasma
with 25 µL of working internal standard (WIS) solution. The WIS was 10 µg/mL NV1057
and was prepared by diluting a 100 µg/mL NV1057/DMSO solution with WIS diluent
solution. WIS diluent being: DMF/HPLC grade Water/FA (50:50;0.1, v/v/v). Formic acid
was used to prevent the compound from aggregating in the solvent and from sticking to
the container.
After the internal standard was added and gently mixed, 75 µL of precipitation
solution was also added. The protein precipitation solution was either acetonitrile with
0.05% acetic acid or methanol (89). The mixture was vortexed, and 200 µL precipitation
solution was added again. The mixture was vortexed again for 10 minutes and centrifuged
at 4000 rpm. The polyamide was extracted with DMSO from both pellet and supernatant
obtained after centrifugation.
2.2.5 Pellet Sample Preparation. Extraction of Genomic DNA from Spiked
Whole Blood and Pellet.
The extraction of genomic DNA from blood cells was performed using the DNAzol
BD (Life Technologies) procedure at room temperature (90). The lysis of the cells was
performed with DNAzol lysing solution, a guanidine-detergent that hydrolyzes RNA and
allows a precipitation of DNA from a cell lysate. (1 mL DNAzol + 0.1 mL liquid sample).
The DNA precipitation with 100% ethanol or isopropanol (lysate + 0.5 mL ethanol/1 mL of
DNAzol) was followed by the precipitated DNA wash (1 mL of 75% ethanol, 2 times).
Subsequently, DNA was solubilized with 8 mM NaOH. DNA isolated with a DNAzol regent
does not resuspend well in water or Tris buffer.
To separate the polyamides from DNA, DNA digestion was performed with a DNAFreeTM–Applied Biosystems (AM1906) kit which contains deoxyribonuclease I (DNase I).
DNase I digest single- and double-stranded DNA to oligodeoxyribonucleotides containing
a 5’-phosphate. DNase I is suitable for removing DNA from samples containing proteins.
Following the digestion of DNA, protein precipitation was performed by two
methods. The first method used was precipitation with acetonitrile + 0.5% acetic acid, the
method proposed by MPI. The second method was based on work done by the Dervan
group and employed methanol (91). The polyamide was extracted from every fraction,
supernatant or pellet, obtained after centrifugations. For polyamide extraction DMSO was
used. If the samples contained cell residues that cannot be removed by centrifugation, the
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samples were filtered and the filter was washed with DMSO until all polyamide was
recovered.
2.2.6 LC-MS Analytical Method
The sample concentrations of polyamide NV1042 were analyzed by LC-MS using
an Agilent 1100 system (Agilent, Santa Clara, CA, USA) connected with an Agilent 1956B
MSD, or single quadrupole mass spectrometer. HPLC separation was accomplished using
a Phenomenex Jupiter Proteo (C12), 4.6 x 50 mm, 4 µm particle size, 90 Å pore size, part
number OOB-4396-EO column. The column temperature during the experimental analysis
was maintained at 40 °C. The mobile phase A consisted of 100% HPLC grade water with
0.1% TFA. The mobile phase B consisted of 100% HPLC grade acetonitrile. The following
gradient program was used: 5% B (0-3 min, 2.0 mL/min), 60% B (4 min, 2.0 mL/min), 60%
B (4.25 min, 2.0 mL/min), 5% B (5.5 min, 2.0 mL/min), and 5% B (6.5 min, 2.0 mL/min).
The total run time for a sample was 6.5 min. The auto-injector temperature was maintained
at RT. The needle wash solution was MeOH. The injection volume used varied between
1 and 100 µL according to the sample concentration. The detection wavelength was set
to 300 nm (Figure 2.3 and 2.5). Data were processed with Agilent ChemStation software,
which was also used to control the HPLC/MS. Positive-mode electrospray ionization of the
compound NV1042 produced abundant, protonated, molecular ions (M+3H+) 3+/3 =842;
(M+2H+) 2+/2 = 1264; (M+H+) +/1 =2526.8 (2M+3H+) 3+/3 = 1684.5 (Figure 2.3). These ions
were generated by the parent species at HPLC retention time 2.9 min. Note that in order
to see good UV/Vis spectra by diode array detection, high concentrations of compound
were injected relative to what was necessary for mass spec detection alone. These high
concentrations were the likely cause of the gas-phase aggregates such as [2M+3H]3+ that
we commonly observed.
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Figure 2.3. Representative mass spectra of NV1042 precursor ions. The positive
electrospray ionization of the NV1042 compound produced abundant protonated
molecular ions (M+3H+) 3+/3 =842; (M+2H+) 2+/2 = 1264. 600<m/z<2300 vs ion current
2.3 Results and Discussion
Whole blood fractionation was performed for separation of the blood plasma from
the blood pellet. Blood plasma, which represents 55% of total blood volume, is the
noncellular liquid part that contains dissolved proteins, glucose, clotting factors,
electrolytes, hormones and carbon dioxide (92).
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The blood pellet is composed of two fractions. The buffy coat consists of
leukocytes (white blood cells) mixed with platelets, and erythrocytes or the red blood cells.
It was proposed that the disappearance of the polyamide molecules in the MPI
samples was caused by the molecules being “trapped” in the cells. To recover the
polyamide, the pellet originating from the sample treated with the highest polyamide
concentration was studied first. Every fraction obtained after centrifugation steps was run
on HPLC.
A standard curve used for quantification was prepared by mixing 1 mL DNAzol +
0.2 mL NaOH (8mM) + 6.4 µL 0.1 M HEPES with various concentrations of polyamide
(Table 2.1, Figure 2.4). HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) is a
zwitterionic organic buffering agent and was used to adjust the pH to 8.4.
Table 2.1. HPLC peak areas obtained following the pellet sample preparation procedure.
(0.1 mL PA + 1 mL DNAzol + 0.2 mL NaOH (8mM) +6.4 µL HEPES 1M)
Sample

Concentration (ng/mL)

Peak area (mAU*s)

Injection volume(μL)

D1

25000

1020,74988

50

D2

5000

198,15282

50

D3

1000

30,21107

50

D4

50

37

100

1200
y = 0.0408x + 0.6186
R² = 0.9994

Area(mAU*s)

1000
800
600
400
200
0
0

5000

10000

15000

20000

25000

30000

Concentration (ng/mL)

Figure 2.4. The standard curve, as determined by linear regression, displayed good
linearity (R2 > 0.99) over the range tested from 50 ng/mL to 25000 ng/mL NV1042.
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The quantity of PA recovered from MPI pellet samples (D and DD spiked with 2.5
µg/mL polyamide) was low but detectable. The highest recovery was 33%. However, when
fresh whole blood was spiked with 2.5 µg/mL NV1042 a higher quantity was recovered
from the blood pellet (cells). When plasma was spiked with the polyamide, the recovery
was almost complete. More than 50% of the polyamide precipitated with the protein
fraction, and the rest was found in the supernatant of the spiked plasma. The highest
protein recovery results were obtained when acetonitrile + 0.5% acetic acid was used for
protein precipitation. It was hypothesized that D5W aided absorption of polyamide into the
cells. (Note: this hypothesis about D5W aiding blood-cell uptake was later confirmed true
for polyamide NV1028 by M.S. student Faten Tamimi working with Dr. G. Davis Harris, Jr.
and Dr. Puhong Liao, and by parallel work at another contract lab, Ricerca Biosciences
(Concord, Ohio), where Ricerca worked with radiolabeled NV1028 whose synthesis was
pioneered in our group by Dr. Puhong Liao.)
Alternatively, it is possible that polyamide NV1042 is taken up and retained by the
lung tissue. This phenomenon has been previously described for drugs given
intravenously (91, 93, 94). The lung serves as a reservoir for exogenous compounds and
as a pathway for elimination. (This alternative was not supported by later radiolabeling
studies at Ricerca, at least with NV1028.)
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2.4 Supplementary Material

Figure 2.5. Representative chromatograms of NV1042. NV1042 in D5W (ECF1025),
NV1042 in plasma fraction (ECF1033). LC-MS Method: 5-60% ACN/0.1% aq. formic acid
over 6 min, 2.0 mL/min, 800-2600 MW. Peaks were detected and integrated at 300 nm.
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Chapter 3
Binding Studies of TMG Asymmetric Hairpin Polyamides (TMG-AHP) NV1078 and
NV1087 with Designed, 120 bp DNA Sequences
3.1 Introduction
The goal of this work was to determine the binding events that take place in vitro
between a designed 120 bp DNA and the two large antiviral TMG polyamides, NV1078,
and NV1087. TMG polyamides contain a modified N-terminus (1, 1, 3, 3
tetramethylguanidine) (Table 1.1 and 1.2, also Figures 3.4 and 3.5). The 120 bp DNA
fragment was designed to eliminate the possibility of superposed or otherwise confused
binding sites.
Superposition of multiple binding sites was often observed when large polyamides
bind to dsDNA and made differentiation among binding sites and determination of all
associated dissociation constants (Kd) impossible in prior reported work (86). It is
impossible to tell which binding site corresponds to the calculated Kd since large
polyamides can bind with high affinity even though the binding sequence is not ideal or
“correct” according to previously-established binding rules (60).
Binding events were determined using DNase I footprinting (11, 86) and affinity
cleavage techniques (95). The binding sites of the polyamides have been analyzed by a
capillary electrophoresis (CE) procedure (86, 96). The dissociation constants (Kd’s)
derived from the isotherms of the binding sites were calculated according to Langmuir and
Hill equations (86, 96, 97) based on assumption that the binding is infinitely cooperative
for all ligands.
3.2 Materials and Methods
3.2.1. Design of the 120 bp DNA Fragments
The 120 bp DNA sequence was designed to include one “perfect matching site”
for PA NV1078 (green) and one perfect matching site for PA NV1087 (red) (Table 3.1).
Binding events have been analyzed for four 120 bp DNA sequences, following systematic
changes in the DNA fragment at TMG binding sites, or locations, to look for sequence
preferences (A changed to T, G, and C). The primers (forward and reverse), used in
polymerase chain reaction (PCR) mutagenesis by overlap extension are presented in
Table 3.1. The primers extended the 90 bp DNA fragment to 120 bp mutated DNA. The
primers’ suitability was analyzed with the Mfold Web Server which predicts secondary
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structure of DNA (or RNA) and can be used for examining the folding possibility or the
hybridization of the primers.
Table 3.2. Primer pairs that extend the 90 bp DNA to 120 bp DNA. The nucleotide
segments that overlap with the fluorescently labeled primers are represented in bold. The
perfect matching site for PA NV1087 is highlighted in red, while green nucleotides show
the perfect matching site for PA NV1078.

A second PCR reaction used the same nucleotide sequence primers labeled with
FAM or HEX dyes attached at the 5’ ends, to label the 120 bp DNA with CE-compatible
fluorescent dye (Table 3.2). 6-FAM specifies the fluorescein dye and HEX designates the
hexa-chlorofluorescein dye (IDT Coralville, Iowa)
Table 3.2. Fluorescently labeled primers

Double-stranded oligonucleotides were formed by annealing equimolar amounts
of complementary single strands by heating at 90 °C for 5 min and cooling the samples to
ambient temperature in 5 mM potassium phosphate and 50 mM NaCl (pH 7.5).
The PCR settings for the 90 bp DNA extension were: 95 °C for 3 min followed by
30 cycles of 95°C for 30 sec. allowing denaturation, 56 °C for 1 min annealing, and 68 °C
for 1 min extension temperature, in the presence of Taq Polymerase (NEB). The DNA
fragments were separated using a 1.2 % agarose gel, visualized with ethidium bromide,
and purified with Qiagen Gel Extraction Kit (Qiagen, Valencia, CA 91355).
The nucleotide order of the 120 bp DNA fragment was verified by Sanger
sequencing (USB Affymetrix Thermosequenase) and Maxam-Gilbert sequencing (96, 98).
For the interpretation of capillary electrophoresis (CE) results and to correctly
assess the footprinting and affinity cleavage events at the nucleotide level, indexing (size
calling) was performed for every 120 bp DNA fragment. Therefore, the hydroxyl radical
cleavage products (99) (which include 3’-phosphate and 3’-phosphoglycolate, with 3’26

phosphate being the primary cleavage product) produced in the affinity cleavage reactions
were correlated with Maxam-Gilbert sequencing products (96). The fragments generated
by DNase I footprinting method (3’-dideoxy ribonucleotide) were associated with the endtermination Sanger products (96).
All primers and DNA oligomers were purchased from Integrated DNA
Technologies, Inc.
3.2.2 Sanger and Maxam-Gilbert Sequencing
The DNA sequences used in the study have either a FAM or a HEX dye on the 5’
end, therefore the mobility of the fragments in the capillary electrophoresis decrease
comparing with the mobility of the same DNA fragment missing the dye. Indexing (size
calling) must be performed for every DNA fragment, to assess the footprinting or cleavage
events correctly at the nucleotide level (86).
According to the chemistry of the fragments generated in the sequencing cleavage
reactions, two different indexing methods were used.
Sanger (USB) sequencing, the end-termination PCR method, correlates the CE
nucleotide position to the real position of the nucleotides on DNA fragment generated in
the DNase I cleavage reactions. (96).

Figure 3.1 Fragments generated in the DNase I reactions and Sanger sequencing
(96).
Maxam-Gilbert Sequencing: in order to correlate the hydroxyl radical cleavage
products (3’-phosphate or 3’-phosphoglycolate) generated in affinity cleavage reactions
with the fragment position in the CE, a second indexing that creates similar cleavage
products is necessary (96). The hydroxyl radical generated by the Fenton reaction
oxidizes DNA by abstracting hydrogen from the deoxyribose ring (99), causing strand
cleavage. In the case of 5’-labeled DNA, the hydroxyl radical cleavage products will be 3’phosphate or 3’-phosphoglycolate. Fragments with 3’-phosphate are the main species
generated in this reaction (Figure 3.2).
In the Maxam-Gilbert method (98), DNA is treated in four different reactions which
cleave at G, A+G, C, and C+T., depending on reagents and conditions: formic acid
depurinates the purines (A+G), while dimethylsulfate methylates G (and some A).
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Pyrimidines (C+T) are hydrolyzed with hydrazine, but addition of NaCl limits this hydrolysis
only to C.
Piperidine is then added to cleave the phosphodiester bond where the base has
been removed and eliminate both phosphates from the sugar.

Figure 3.2. Fragments generated in affinity cleavage reactions and MaxamGilbert sequencing (96) .
The fragments generated via end termination PCR technique have a 3’-dideoxy
ribonucleotide, and moves slower by CE than the corresponding fragment produced by
OH radicals, which has the 3’-phosphate end (96).
3.2.3 Quantitative Deoxyribonuclease I (DNase I) Footprinting
DNase I footprinting method by capillary electrophoresis (CE) was employed to
determine the binding affinities of TMG polyamides. The four fluorescently-labeled 120 bp
DNA segments were used for performing DNase I footprinting titration experiments.
Double-stranded DNA (500 pM, 200 pM and 50 pM) was incubated in presence TKMC
buffer (with the following composition: 10 mM Tris, 10 mM KCl, 5 mM MgCl2 and 5 mM
CaCl2) and 10% final concentration CHAPS (10mM) at 37 °C for 5 hours with polyamides
in a concentration range from 0.2 nM to 60 nM according with protocols previously
published (57, 86). The samples were digested with the adjusted amount of RQ1 RNaseFree DNase I (Promega, Madison, WI) for 5 min at 37 °C and the reactions were quenched
with 200 mM EDTA. The DNase I digested products, obtained following single hit kinetics
procedure, were purified with Qiagen PCR purification kit (Qiagen, Valencia, CA) and
eluted from column with elution buffer (EB, Tris-Cl, pH 8.5) (57).
The samples were analyzed using an ABI 3730Xl DNA Analyzer using Genescan
600 LIZ as internal lane standard at DNA Core Facility at the University of Missouri. Data
were processed using GeneMarker V2.4.0 Software Softgenetics LLC, State Collage, PA.
For the interpretation of the electropherograms, the DNase I cleavage products were
correlated with Sanger sequencing results of the same fragments.
For the quantitative analysis of the electropherograms KaleidaGraph 4.1 software
as fitted to the Hill and Langmuir isotherms was employed.
28

3.2.4 Affinity Cleavage Assay (AC). Orientation of the TMG-AHP
The four fluorescently-labeled 120 bp DNA segments were used for performing
affinity cleavage experiments. In the case of both polyamides, NV1078 and NV1087,
chelating agent, EDTA, was covalently linked to the C-terminus (primary amine of the Ta
tail) of the polyamides. The PA-EDTA conjugate was incubated with 0.8 equivalence of
Fe(NH4)2(SO4)2 to form PA-EDTA-Fe(II) derivatives A volume of 100 μL of 1nM DNA was
incubated with PA-EDTA-Fe(II) conjugate at concentrations ranging from 5 nM to 100 nM.
The results were registered for 10, 25 or 100 nM. The reaction mixture contained 10 mM
Tris, 10mM CHAPS at pH 7.5. The cleavage reaction of the OH radicals formed in a
Fenton reaction (see results) was initiated, activated by adding 100 mM DTT reducing
agent (86, 98, 100) for a 4-hour incubation time. The reaction was stopped, and the
products were purified using Qiagen PCR purification kit.
The samples were analyzed using an ABI 3730Xl DNA Analyzer using Genescan
600 LIZ as internal lane standard at DNA Core Facility at the University of Missouri. Data
were processed with GeneMarker V2.4.0 Software Softgenetics LLC, State Collage, PA.
For the interpretation of the electropherograms, the hydroxyl radical cleavage products
were correlated with Maxam-Gilbert sequencing results of the same fragments (see
sequencing).
3.3 Results and Discussion. Binding preferences of NV1078 and NV1087
The sequencing results are included in the tables “Size calling 120 XX1 top strand”
and “Size calling 120 XX1 bottom strand” where X1=A, T, C, G, for every strand. The
mutation sites that have to be followed were confirmed as follow:
For 120 bp XA (ECF2141): On top strand: peak 81.3, corresponding to real position
88, shows A; On bottom strand: peak 24.4 corresponding to the actual position 88 shows
T, peak 88.4 corresponding to position 26 shows T.
For 120 bp XT (ECF3043): On top strand: peak 81, corresponding to real position
88, shows T; On bottom strand: peak 88.4 corresponding to position 26 shows A.
For 120 bp XC (ECF2142): On top strand: peak 81, corresponding to real position
88, shows C; On bottom strand: peak 88.7 corresponding to position 26 shows G.
For 120 bp XG (ECF2159): On top strand: peak 81.2, corresponding to real
position 88, shows G; On bottom strand: peak 88.1 corresponding to position 26 shows
C.
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Figure 3.3. Example of Sanger (USB) sequencing electropherogram for 120XC
in FAM channel
Quantitative (DNase I) footprinting assay along with affinity cleavage by capillary
electrophoresis (CE) was used to assign the TMG binding preferences of NV1078 and
NV1087 polyamides. Binding events have been analyzed for designed 120 bp DNA
sequence (see methods) following systematic changes in the DNA fragment at TMG
binding sites or locations (A changed to T, G, and C) to map and quantify dsDNApolyamide interactions. Fluorescently-labeled DNA (5’-FAM at the top strand and 5’-HEX
for the bottom strand) incubated with varying PA concentrations was used to detect the
binding locations (DNase I) and the binding orientation (affinity cleavage) of the
polyamides.
DNase I is an enzyme that cleaves the phosphodiester backbone of the DNA
double helix (101) relatively nonspecifically (sometimes AT rich sequences being
disfavored) (101-103). If no polyamide is bound to the DNA, the digestion will encompass
the whole fragment. However, if the polyamide is bound to the DNA, that particular region
will not be nicked as much as the polyamide-free control (86). Therefore, the DNase I
assay detects DNA-polyamide interactions based on the fact that (reversibly) bound
polyamide protects DNA from enzymatic cleavage. The assay uses DNase I enzyme that
cleaves the phosphodiester backbone of the DNA double helix in the presence of divalent
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cations, introducing single-stranded incisions through hydrolysis of the P–O-C3′ bond
(101, 102, 104).
The DNase cleavage pattern of the DNA in the absence of the polyamide is
compared to the cleavage pattern of the same DNA sequence in the presence of
increasing concentrations of polyamide (from 0.2 nM to 60 nM).
The first round of DNase I footprint experiments explored the binding of PA’s to
500 pM of 120 bp DNA followed by experiments using 200 pM substrate (dsDNA)
concentration. The electropherograms showed saturation below 5 nM PA. Consequently,
the PA’s concentration range was lowered from 0, 1, 2, 5, 10, 20, 40, 60 nM to 0, 0.2, 0.3,
0.5, 1, 2, 5, 10 nM. To maintain the proper equilibrium conditions (ligand excess comparing
with the substrate concentration; the ligand should be at least five times in excess (97) the
DNA concentration was dropped to 50 pM.
The binding measurements were performed after sufficient time (5 hours) to allow
the system to reach equilibrium. Therefore, the equilibrium dissociation constant (Kd), the
inverse measure of the affinity of the polyamide to dsDNA, and the Hill coefficients were
determined in a closed system, under equilibrium conditions. The peak areas (DNase I
experiments) or heights (AC experiments) of the resulting electropherograms were taken
into consideration. The peak areas in the protected regions were normalized to a
neighboring control peak not susceptible to polyamide concentration and plotted as
fraction bound vs. TMG-AHP concentration (11, 105).
The electropherogram results were fitted to the Hill (n=1) and Langmuir isotherms
based on the assumption that the binding is infinitely cooperative for all ligands. From the
fractional saturation θ (Eq. 1), or fraction bound, where L is the free polyamide
concentration (97), the apparent dissociation constants, Kds, for the binding sites, and the
Hill coefficients (n) were determined, and the results are presented in Tables 3.2 and 3.3
θ = ([L]n/Kdn) / (1 + ([L]n/Kdn))

(Eq.1)

θ = (Ka [PA]) n /1+ (Ka [PA]) n

(Eq.2)

KaleidaGraph 4.1 software outputs the results of the processed data in the form of Eq 2.
The chelating agent, EDTA, was covalently linked to the C-terminus (primary
amine of the Ta tail) of the polyamides and the complex was ligated to iron (II). The
complex cleaves DNA strand near the polyamide C-terminus binding site following binding
of the polyamide in the minor groove. During the reaction, molecular oxygen is reduced to
hydrogen peroxide in situ (106), followed by Fenton-type chemistry responsible for the
production of hydroxyl radicals (107). The hydroxyl radicals generated via Fenton reaction
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cleaves the DNA strand near the polyamide C-terminus binding site (up to 2, 3 nucleotides
near the Ta-EDTA end) by abstracting hydrogen (H•) from deoxyribose phosphate in the
DNA backbone (99) (Figure 3.3).
Fenton reaction: [Fe (EDTA)]2- + H2O2 → [Fe (EDTA)]- + OH- + •OH
The affinity cleavage results give information about the orientation of the
polyamides. Hairpin PAs align to adjacent DNA strand in two different ways. N-terminus
(TMG) to C terminus (3, 3-diamino-N-methyldiproprylamine: Ta) parallel to the 5’-3’
direction of the adjacent DNA strand, as shown in Figures 3.4A and 3.5A, called forward
binding, or N to C terminus parallel to the 3’-5’ direction, as shown in Figures 3.4B and
3.5B, called reverse binding.

A

B

Figure 3.4. The structure of hairpin TMG NV1078 polyamide and the code of DNA
recognition upon binding to DNA (W: A or T; X, Y: unknown nucleotides). Binding models:
filled circles represent imidazole rings; open circles represent pyrrole rings; curves-linking
circles represent γ-aminobutyric acid; diamonds represent β-alanine; the triangle
represents TMG. (A) Forward binding, (B) reverse binding.

A

B

Figure 3.5. The structure of hairpin TMG NV1087 polyamide and the code of DNA
recognition upon binding to DNA (W: A or T; X, Y: unknown nucleotides). Binding models:
filled circles represent imidazole rings; open circles represent pyrrole rings; curves-linking
circles represent γ-aminobutyric acid; diamonds represent β-alanine; the triangle
represents TMG. (A) Forward binding, (B) reverse binding.
When the polyamides align to a sequence suggested by the recognition rules
defined by Dervan (54, 60) as in Figures 3.4 and 3.5, the binding site is considered a
perfect match site. The mismatched sites are the sites where the polyamide aligns to a
DNA sequence that is different. For example, a guanine (G) or a cytosine (C) appears in
the place of A or T or imidazole aligns to a nucleotide that is different than G.
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The binding affinity of PA and PA-EDTA conjugates is similar as demonstrated in
the binding study of PA1 (11). The conjugated EDTA group removes one positive charge
and adds three negative charges to the polyamide when not bound by Fe(II) (11).
3.3.1 Binding preferences of NV1078
The Map in Figure 3.6 presents the 120bp DNA sequence and the variety of
possibilities of polyamide NV1078 to bind in the minor groove of the ds DNA. The cleavage
pattern of the control samples can be compared with the cleavage pattern of the sample
treated with 0.5 nM NV1078. The affinity cleavage sites are depicted with the help of the
vertical arrows, while and related electropherograms display the DNase I protection sites.
The data represents the interpretation of the following experiments: DNase I
Footprinting of 50 pM DNA (ECF3011, ECF3018, ECF3030, ECF3058); Sequencing with
USB Kit (ECF2142); Affinity cleavage: 1 nM DNA and 25 nM NV1078 (ECF3037); MaxamGilbert Sequencing (ECF2135).

Figure 3.6. Map of 120 XC bp DNA. The first two electropherograms provide
information for the top DNA strand, labeled at 5’ with FAM dye. The electropherograms in
the HEX channel correspond to the mirror image of the bottom nucleotide strand.
Nucleotides marked in red are the integration sites, were the dissociation constant values
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Kd’s were determined. The regions outside the boxes the protected areas were NV1078
binds with high affinity.
The data gathered from electropherograms have been used to calculate the
apparent fractional saturation θ (the fraction of polyamide bound to the DNA). The
isotherms, fraction bound vs. polyamide concentration, allow the calculation of
association/dissociation constants and Hill coefficient.
For the integration site, the fraction bound was calculated as in Eq.3, where Isite
represents the fluorescence intensity, the peak height in a footprint region, and Iref is the
peak height of a reference site that does not change in intensity during titration. I0 and I0ref,
as in Eq.4, are the intensities of the sample peak and reference peak in the control
samples (just DNA cut by DNase I or hydroxyl radicals, without polyamide treatment). To
obtain the apparent fractional saturation, θ, the results were normalized to one.
Θ = Isite /Iref;

(Eq.3)

Θ0 =I0site/I0ref

(Eq.4)

Θapp =1-Θ/Θ0 (Eq.5)

Figure 3.7. Isotherm (KaleidaGraph 4.1 software). Results according with
Langmuir equation (upper table) and Hill equation (lower table) of 120 bp DNA, [DNA] =
50 pM, incubated with NV1078 (0 - 10 nM) and digested with 0.35 U DNase I.
The results derived from Hill equation (Eq.2) in this particular case (Figure 3.7) are:
Kd = 1/3.5 = 0.74 nM; Hill coefficient, n = 1
From the cumulative DNase I and affinity cleavage data on the 120bp DNA, three
binding sites for TMG-AHP NV1078 were identified. The dissociation constants have been
calculated from the isotherms obtained in at least three independent experiments. The
detailed results are presented in the appendix and in the supplementary material.
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(Appendix 1: Dissociation/association constants: NV1078 & 120 bp 50 pM DNA; Figure
3.11: Isotherm triplicates: NV1078 120 bp, 50 pM DNA).

Table 3.2. Summary of Hill dissociation constants for four binding sites on 120XA,
120XT, 120XC, 120XG DNA of NV1078. The polyamide tail binding site is highlighted in
red

Table 3.3. Summary of Hill association constants for four binding sites on 120XA,
120XT, 120XC, 120XG DNA of NV1078. The polyamide tail binding site is highlighted in
red

The first binding site, not influenced by mutations (pos. 27-39, 1) in Figure 3.6, is
a forward binding site where NV1078 tolerates well two mismatched (mm) nucleotides.
The high cooperativity at this location shows that an alternative binding mode is also
probable at this site, namely a two-mm forward (29-41) site, not supported by AC sites,
where the tail binds TATT, TMG at T.
Binding site no. 2 (pos. 59-71), Figure 3.6, holds the potential for superposition of
different binding sites. This site can be associated with a forward 0-mm binding (2a,
5’TGTAATATGTTTT3’) or a 0-mm reverse fashion (2c, 5’TTTTGTAAATTCT3’). This
binding site is not affected by mutations and shows a nearly constant Kd (Appendix 1).
The affinity cleavage patterns suggest that 0-mm reverse binding is preferred over forward
binding.
According to the dissociation constant values for the third binding site Figure 3.6,
3 (position 85-97), the location with systematic changes in the DNA fragment at TMG
binding sites, shows preference for C and T (Table 3.2, Fig. 3.8). The presence of G is
less-preferred than C, T or A at the TMG binding site or location.

35

S U M M AR Y O F TH E H I L L D I S S O C I ATI O N
C O NS TAN TS F O R T HE B I N D I N G S I TE S O N 1 2 0 B P
DNA OF NV1078
KdHill (nM) T

KdHill (nM) C

KdHill (nM) G

0.18

0.35

0.42
0.24

0.22

0.23

0.29

0.28

0.38

0.35

0.35

KD (nM)

0.67

KdHill (nM) A

5' ATX-TATATTAAGTGCA-TTT 3' 5' ATG-TTTTGTAAATTCT-AAC 3' 5' GCG-ATAXAATTGATTA-CGC 3'

Figure 3.8. Dissociation constants for the binding sites on 120 bp DNA of NV1078,
based on Table 3.2
3.3.2 Binding preferences of NV1087
The dissociation constants have been calculated from the isotherms obtained in at
least three independent experiments. The detailed results are presented in the appendix.
(Appendix 2: KaleidaGraph data NV1087 for 120 bp DNA at 50 pM;), Table 3.4, Figure
3.9., and Figure 3.12 (KaleidaGraph Isotherms NV1087 120 bp).
The binding profile of NV1087 on the same 120 bp DNA sequence revealed four
binding sites. Binding of NV1087 in site no.1 (position 24-37), the position with systematic
changes in the DNA fragment at TMG binding sites, derived from dissociation constant
values, shows a preference for C, T, and A (Table 3.4, Fig. 3.5). Binding site no. 2
(position 55-68) one mm forward binding site is not affected by mutations. Binding site no.
3 (position 66-79) one mismatch reverse binding site is not affected by mutations and is
also the most tightly bound site. Binding site no. 4 (position 87-100), 2mm reverse binding
site is not affected by mutations.
Table 3.4. Summary of Kd values obtained for NV1087. The polyamide tail binding
site is highlighted in red
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S UM M AR Y O F TH E HI L L D I S S O C I ATI O N C O N S TAN T S
F O R T HE B I N D I N G S I TE S O N 1 2 0 B P D N A O F N V 1 0 8 7
KdHill (nM) T

KdHill (nM) C

KdHill (nM) G

5' CCG-ATXTATATTAAGTGCA 3'

0.61
0.4

0.33

0.22

5' TTT-TGTAAATTCTAACCTG 3'

0.34

0.51

5' CTG-TAATATGTTTTGTAAA 3'

0.24

0.19

0.3

0.45

0.36

0.28

0.28

0.42

0.6

KD (NM)

0.93

KdHill (nM) A

5' TTG-CGTAATCAATTYTATC 3'

Figure 3.9. Dissociation constants for the binding sites on 120 bp DNA of NV1087
based on Table 3.4.

Figure 3.10. Binding of NV1087 in position #1, the position with systematic
changes in the DNA fragment at TMG binding or location sites derived from association
constant values, the probability plot shows preference for C, T, and A. (WebLogo 3.4)
3.4 Conclusion
The goal of this work was to provide a detailed binding site analysis illustrating how
polyamide NV1078 and NV1087 can bind the specified 120 bp DNA sequence. The
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second aim was to determine how the DNA sequence where the polyamide tail binds can
influence the binding affinity.
In the AC experiments, all significant binding sites appeared at 10 nM PA and
became clearer at 25 nM PA. Indexing (size calling) of the electropherograms was
achieved with Sanger and Maxam-Gilbert sequencing (11). The 3’ shift between the
forward and revers strands characteristic for minor groove binders (108) was observed.
Although reverse orientation is considered less favorable for small polyamides (109), such
patterns are seen for large polyamides in association with the specified DNA fragment.
Reverse binding was detected in the present work and also in recent studies of my
colleagues (11, 86, 105).
The results for NV1078 show very tight binding for the forward perfect-binding site
(Kd = 0.23-0.7 nM), the highest value being registered when TMG binds G, or is located
next to G (Table 3.2 and Figure 3.8, binding site #3). However, the reverse perfect match
site when TMG binds to T presents the same low value (at site #2). Site #1, a twomismatch forward-binding site is independent of mutations, having similar Kd values of
about 0.3 nM in every strand (TMG at A).
Polyamide NV1087 binds in four different sites (Table 3.4). The forward, perfectbinding site presents slightly higher Kd values when TMG binds to G. One-mismatch
reverse (TMG at A) has the lowest Kd (0.2 nM), very close to one-mismatch forward (0.4
nM) (TMG at A).
The binding of the polyamides is influenced not just by the nucleotide position at
the TMG site but also by the entire nucleotide sequence at the tail of the polyamides. If
the polyamides tail bind to A, T, or C, the binding affinity is increased. The presence of G
nucleotide is less-preferred than T, C or A at the TMG site for both TMG-AHPs
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3.5 Supplementary material
Figure 3.11: Isotherm triplicates of 3 binding sites of NV1078 on 4 DNA sequences. (120
bp DNA, 50 pM DNA)
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Figure 3. 12: Isotherm triplicates of 4 binding sites of NV1087 on 4 DNA sequences. (120
bp DNA, 50 pM DNA)
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Chapter 4
Interactions Between two TMG Asymmetric Hairpin Polyamides (TMG-AHP),
NV1078 and NV1087, with the HPV16,18 LCR segment
4.1Abstract
Long-term, persistent infection with high-risk strains of human papillomavirus
(HPV) is the precursor of most of the cervical carcinomas and an increasing number of
oropharyngeal squamous cell carcinomas which represent 90-95% of head and neck
cancers (3). While the vaccines can protect the targeted population of possible infections
(4), no HPV antiviral drugs are available for the definitive treatment of preexisting or future
viral infections. To treat current or future HPV infections, drugs that selectively block virusspecific processes, but do not damage the host cells, are needed.
The antiviral compounds employed in the present study, NV1078 and NV1087,
represent a subclass of the heterocyclic oligomers known as N-methylpyrrole Nmethylimidazole (Py-Im) polyamides (PAs). They have a modified N-terminus capping
group, 1,1,3,3 tetramethylguanidine (TMG) and an asymmetric structure (26), and will be
referred to as TMG-AHPs for TMG-Asymmetric Hairpin Polyamides. It has been
demonstrated (Edwards, T. and Fisher, C.) that the two compounds possess the unique
property of unusual antiviral activity against three high-risk HPV strains (HPV16, HPV18,
and HPV31) (Table 1). The antiviral compounds eliminate the viral load of infected
keratinocytes without integration of the viral DNA episomes in the host chromosome. The
TMG-AHPs are analogs of natural products Distamycin A and Netropsin that function, as
has been recently determined (5, 6), by interfering with natural virus-host interactions and
by stimulating the host cell’s DNA Damage Response to destroy viral DNA.
The interactions between the aforementioned polyamides and LCR of viral HPV16
and HPV18 DNA fragments were studied to determine the DNA sequence specificity and
binding sites of the polyamides, to help establish the TMG-AHP’s mechanism of action.
The quantitative deoxyribonuclease I (DNase I) footprinting method was used (11, 97),
along with affinity cleavage assays (95), to map and measure the interactions between
fluorescently labeled DNA and the active TMG-AHPs. The dsDNA-AHPs binding locations
were detected and quantified by capillary electrophoresis (110).
Results in this chapter demonstrate that TMG-AHPs 1078 and 1087 recognize 13
nucleotides, and bind with nanomolar affinity to the expected binding sites, as well as one43

, two-, and even three-mismatch (sites of polyamide binding with a DNA sequence
containing one or more bases that do not correspond to the expected polyamide binding
sequence) binding sites. Moreover, it was observed that the asymmetric polyamides
(APAs) have a conclusive preference for the region adjacent and overlapping with E1 and
E2 viral proteins binding sites, where both polyamides bind in a cluster. The data indicate
that viral replication for HPV could be disturbed by TMG-AHPs binding at numerous sites
with high affinity for the sequence (7880-30) of the HPV16 viral LCR DNA or the preferred
binding region of HPV18 LCR (7841-43).
4.2 Introduction
Although human papillomavirus (HPV) vaccines have been developed (4), the
occurrence of HPV infections is still extremely prevalent. To treat the already existent or
future viral infections, drugs that selectively block virus-specific processes but do not
damage the host cells are needed. Persistent infection causes genomic instability and
eventually the integration of the viral genome into the host chromosomes (111, 112), and
is the main reason for neoplasia and cancer. The elimination of viral DNA during the
maintenance stage of a persistent infection is the strategy behind the discovery of the
antiviral compounds described here.
The genetic information of Human Papillomaviruses is stored in small,
chromatinized circular dsDNA viral genome (episome) that typically contains 8 genes (27).
The HPV genome is approximately 8000 base pairs long. Since the viral genome does not
encode any polymerases, the only viral enzyme being E1 (an NTPase / helicase), the
maintenance of viral load depends on the host, infected keratinocyte cells’ replication
machinery. Two viral proteins E1 and E2 also have decisive roles in most replication
pathways. These viral proteins recruit host proteins, including DNA polymerase alpha and
many proteins which are part of the DNA Damage Response (DDR) defense mechanism
(8, 9, 15, 48, 113, 114), to initiate and enable the replication process. Also, these viral
proteins may serve as bridges between the viral genome and the cellular chromatin (36),
ensuring participation of the viral proteins to the replication process. It is important to
mention that opposing many studies supporting the importance of E1 and E2 in the viral
lifecycle, it was also shown (using various transfected cell lines) that a different replication
mechanism, independent of viral trans-factors, E1 and E2 (115), is also possible. HPV
DNA is capable of replicating by either random choice or a once-per-S-phase mechanism,
depending on cell type and levels of E1 protein (33). In the particular case of W12E cells,

44

a once-per-S-phase replication mechanism, dependent on E1 and E2, is most frequently
observed (116).
Previous studies (10-12, 112, 117) have shown that viral dsDNA can be targeted
using small molecules such as pyrrole-imidazole polyamides, homologs of natural
products Distamycin A and Netropsin (49). To overcome the high toxicity but maintain
antiviral properties of the minor groove binders Distamycin A and Netropsin, hairpin Nmethylpyrrole-N-methylimidazole (Py-Im) polyamides (PAs) were designed (54, 60). To
exert their effect, the polyamides have to reach and bind to their cellular target, the viral
dsDNA in the nuclei. Slight, sometimes minimal structural changes of the compounds may
result in distinct cellular or nuclear distribution with dramatic changes of biological activity.
Efficient cellular uptake of hairpin PAs was observed in human keratinocytes harboring
high-risk HPV episomes (5, 6, 10). Hairpin polyamides specifically recognize and bind with
high (nanomolar) affinity to dsDNA in minor groove regions by hydrogen-bonds (Fig.1)
(49, 59). The binding of PAs is followed by alterations of the dsDNA shape by widening
the minor grove, narrowing the major groove (54, 60), and stiffening the double helix
(61).The introduction of β-alanine building blocks confer additional flexibility for the
molecules and permit a better mimic of the DNA curvature (55, 57). By binding with high
affinity in the minor groove, polyamides displace proteins from DNA, interfering with
natural processes (62) and acting as transcriptional activators or repressors.
To decrease or eliminate the HPV viral DNA (episomes) from infected keratinocyte
cells, a library of more than 100 polyamides was synthesized. It was found that some of
the long hairpin polyamides are active against high-risk HPV strains (HPV16, HPV18, or
HPV31) (5, 6, 10-12, 26) and cause a substantial decrease of the HPV DNA episome
levels, eradicating the viral load (amount of viral DNA per cell) in undifferentiated
keratinocyte monolayers, in the absence of integration of viral DNA (5, 6, 117). A minimum
of 10 DNA base-pair coverage is necessary for viral activity (10).
Among the newly synthesized polyamides (work by Kevin J. Koeller, G. Davis
Harris. Jr.), two stand out as having the greatest antiviral activity against three high-risk
HPV strains: HPV16, HPV18, and HPV31 (26) (Table 4.1). The two polyamides employed
in the present study, NV1078 and NV1087, have a modified N-terminus capping group,
1,1,3,3 tetramethylguanidine (TMG) and an asymmetric hairpin structure (TMG-AHP).
These distinct polyamides have the ability to decrease HPV16, 18, and 31 episome levels
in undifferentiated W12E cell monolayers and tissue culture, in the absence of integration
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of viral DNA, with greater efficacy than NV1042, the most potent compound published,
considered the lead compound (work by Terri G. Edwards, NanoVir LLC).
The interactions between the above-mentioned polyamides and LCR of viral
HPV16 and HPV18 DNA fragments were studied to determine the DNA sequence
specificity and binding sites of the polyamides, to help establish the TMG-AHP’s
mechanism of action. The studied DNA sequence includes the core replication origin
containing the cis-elements (which do not code for proteins or RNA) imperative in the
process of DNA replication: one E1 protein binding sequence, and the three important E2
binding sites (E2BS1, E2BS2, and E2BS3) (118). The E1BS for HPV16 sometimes
referred to as the origin-binding domain (OBD), is an 18 base-pair sequence:
5’ATAATACTAAACTACAAT3’ (HPV16 episome sequence: 7895-8). The DNA fragment
also contains A/T rich regions surrounding the E1BS and E2BSs and transcription factor
binding sites.
4.2 Methods
The methods used in this work were DNase I footprinting to determine the binding
affinities of the TMG polyamides and the affinity cleavage assay (AC) to ascertain the
orientation of the TMG-AH polyamides. A detailed description of the methods is provided
in Chapter 3.
In addition, the HPV16 LCR 7662-122 bp fragment was generated by Polymerase
Chain Reaction (PCR). The primers employed in reaction were: (forward) 5’-FAM-TAA
ATC ACTATG CGC CAA CGC-3’ and (reverse) 5’-HEX-CCT GTG GGT CCT GAA ACA
TTG-3’. All oligonucleotides were obtained from IDT (Coralville, Iowa).
4.3 Results
The

polyamide

NV1078

has

the

following

composition:

TMG-

PβPPImβPPβγPPβPPPβPPPβTa, where Im represents N-methylimidazole, Py stands for
N-methylpyrrole,

β–alanine,

γ

is

γ-aminobutyric

acid,

and

Ta

represents

CH3N(CH2CH2CH2NH2)2 or 3,3’-diamino-N-methyldipropylamine. NV1078 is present in
solution as a TFA salt. According to the published pairing rules (54, 60) the perfect binding
site for NV1078 will be: 5’-XXXWWWWGWWWW-3’ where W=A or T, and X stands for
the unknown nucleotides for TMG binding. The hairpin structure and the mode of binding
to dsDNA it is showed in Figure 4.1.
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(a)
(b)
Figure 4.1. The structure of hairpin TMG NV1078 polyamide and the code of DNA
recognition upon binding to DNA (W: A or T; X, Y: unknown nucleotides). Binding
models: filled circles represent imidazole rings; open circles represent pyrrole rings;
curves-linking circles represent γ-aminobutyric acid; diamonds represent β-alanine; the
triangle represents TMG. (A) Forward binding corresponds to N to C/5’ to 3’
orientation, while reverse binding (B) corresponds to N to C/3’ to 5’ direction.
The

polyamide

NV1087

has

the

following

structure:

TMG-

PPPβPPβPImγPβPPβPPPβPβTa, where Im represents N-methylimidazole, Py stands for
N-methylpyrrole, β is β–alanine, γ is γ-aminobutyric acid, and Ta represents
CH3N(CH2CH2CH2NH2)2 or 3,3’-diamino-N-methyldipropylamine. According to the pairing
rules (54, 60) the perfect forward binding site for NV1087 will be: 5’ X-X-X-W-W-W-W-WW-W-W-G-W 3’ where W=A or T, and X stands for the unknown nucleotide for TMG
binding (Figure 4.2).

(a)
(b)
Figure 4.2. The structure of hairpin TMG NV1087 polyamide and the code of DNA
recognition upon binding to DNA (W: A or T; X, Y: unknown nucleotides). Binding
models: filled circles represent imidazole rings; open circles represent pyrrole rings;
curves-linking circles represent γ-aminobutyric acid; diamonds represent β-alanine; the
triangle represents TMG. (A) Forward binding corresponds to N to C/5’ to 3’
orientation, while reverse binding (B) corresponds to N to C/3’ to 5’ direction.
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4.4.1 NV1078 polyamide binding sites on 365 bp natural HPV16 (7662-122)
sequence
The first goal of this study was to provide a detailed binding site analysis,
illustrating the binding ability of polyamide NV1078 to the specified DNA sequence. The
HPV16 LCR (GeneBank AF125673.1LCR) region contains cis-acting elements that
regulate transcription and replication of viral DNA (118).
The studied DNA sequence 7662-122 includes one E1 protein binding sequence,
and the three essential E2 binding sites: E2BS1 (35-46), E2BS2 (50-61), and E2BS3
(7858-7869), as shown by the green boxes (Figure 4.3). The E1BS for HPV16, referred
to

as

the

origin-binding

domain

(OBD),

is

an

18

base-pair

sequence:

5’ATAATACTAAACTACAAT3’ (HPV16 episome sequence: 7895-8) (27). The DNA
fragment also contains A/T rich regions surrounding the E1BS and E2BSs and
transcription factor binding sites (SP1, TATA motif).
The binding of E2 viral protein to its binding sites and recruitment of E1 viral protein
to form a double hexamer is fundamental to viral DNA replication (119). The mapping
studies based on data gathered from the DNase I and affinity cleavage experiments
indicate that the polyamide NV1078 binds with high affinity to multiple sites adjacent to
and overlapping with the E1BS and E2BSs.
The binding information is presented in the ECF3097 Map (Figure 4.3) as well as
Tables 4.1 and 4.2.
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Figure 4.3. Binding sites of NV1078 on 365 bp LCR HPV16 fragment. Horizontal
arrows depicting the binding sites are color coded. Black arrow shows perfect binding
site; Red arrow - single mismatch (mm) site; Purple arrow - double mm; Blue arrow - triple
mm; Green arrow - quadruple mm; Solid arrow - forward fashion of PA binding; Dashes
arrow - reverse fashion of PA binding; Green boxes show E2 binding sites; Red letters
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represent the integration peaks; Blue or green letters represent the reference peaks. Red
numbers show the dissociation constant values Kd [nM] presented in Table 4.2. The
yellow background highlights the footprinting regions. Red AC sites are present just at
high polyamide concentrations (100 nM).
A total of 16 binding sites were identified according to the affinity cleavage
patterns. The binding sites and the corresponding nucleotide sequences are presented in
the Tables 1 and 2. The affinity cleavage patterns (vertical arrows) indicate the position of
the PA tail (Figures 4.3) where the hydroxyl radicals are formed (Chapter 3).
The hydroxyl radical cleavage pattern provides information about the PA binding
site and the orientation (forward or reverse) as described above. Horizontal arrows show
the polyamide binding sites, which may only be occupied by a single polyamide molecule
at a time. The length of the arrow corresponds to the DNA sequence to which the
polyamide is bound, while the arrow color coding relates to the literature binding rules.
The binding of the polyamides in the minor groove is an equilibrium process.
The polyamide associates and dissociates from the minor groove and rapidly
rebinds in an alternative way if possible, resulting in a variety of binding patterns. The
majority of the sites permit alternative binding modes. Also, overlapping binding sites are
often present.
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Table 4.1. Binding sites of TMG-AHP, NV1078 on HPV16 (7662-122) fragment. The 13
nucleotide binding sequence of the polyamide has been shown with the associated 5
nucleotide flanking sequences. Blue letters indicate the TMG binding site and the
highlighted guanine G indicate imidazole binding site.

AC
site
0
0
0
1
1
1
2
2
2
2
3
3
3
4
4
4
5
5
6
6
7a
7a
7b
7b
7c
7c
8
9
9

Sequence 5'-3' (XXXXWWWWGWWWW)

Mismatch
type

Position

Binding
fashion

PA tail 5'3'

GGCAC-ATATTTTTGGCTT-GTTTT
GCACA-TATTTTTGGCTTG-TTTTA
TTTAA-ACAAGCCAAAAAT-ATGTA
ATTAG-GTTAGTTAAAACA-AGCCA
GGCTT-GTTTTAACTAACC-TAATT
AATTA-GGTTAGTTAAAAC-AAGCC
ATGCA-ATTAGGTTAGTTA-AAACA
TTTTA-ACTAACCTAATTG-CATAT
ATATG-CAATTAGGTTAGT-TAAAA
TTAGT-TAAAACAAGCCAA-AAATA
TGCAA-TTAGGTTAGTTAA-AACAA
AAATA-TGCAATTAGGTTA-GTTAA
AATTG-CATATTTGGCATA-AGGTT
TTATG-CCAAATATGCAAT-TAGGT
AACCT-AATTGCATATTTG-GCATA
TATTT-GGCATAAGGTTTA-AACTT

2
3

7705-7717
7706-7718

forward
forward

ATAT
TATT

3

7707-7719

reverse (BS)

AAAT

1
4

7717-7729
7718-7730

reverse (BS)
forward

AACA
GTTT

4

7718-7730

reverse (BS)

AAAC

1
4
4

7722-7734
7723-7735
7723-7735

reverse (BS)
forward
reverse (BS)

GTTA
ACTA
TAGT

3

7711-7723

forward (BS)

TAAA

1

forward (BS)

TTAG

1

7721-7733
7726-7738

forward (BS)

TGCA

2

7737-7749

forward

CATA

1
1

7733-7745
7731-7743

forward (BS)
reverse

CCAA
TTTG

1

7744-7756

forward

GGCA

TGGCA-TAAGGTTTAAACT-TCTAA
ATTTA-GTTGGCCTTAGAA-GTTTA
AGGGT-GACATTTAGTTGG-CCTTA
AAATG-TCACCCTAGTTCA-TACAT
ACATG-AACTGTGTAAAGG-TTAGT
ATGAA-CAATGTATGACTA-ACCTT

1

7748-7760

reverse

AACT

4

7760-7772

reverse (BS)

AGAA

2

7768-7780

forward (BS)

GACA

4

7779-7791

forward

TCAC

4

7798-7810

reverse

AAGG

2

7812-7824

reverse (BS)

ACTA

TGTGT-AAAGGTTAGTCAT-ACATT
TTTAC-AAATGAACAATGT-ATGAC
ACAAA-TGAACAATGTATG-ACTAA
ACATT-GTTCATTTGTAAA-ACTGC

1

7806-7818

reverse

TCAT

1

7819-7831

reverse (BS)

ATGT

2

7816-7828

forward (BS)

TGAA

0

7824-7836

forward

GTTC

TGTTC-ATTTGTAAAACTG-CACAT
GCAAA-CCGTTTTGGGTTA-CACAT
CAAAC-CGTTTTGGGTTAC-ACATT

0

7828-7840

reverse

ACTG

2

7859-7871

forward

CCGT

3

7860-7872

forward

CGTT
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AC
site

Sequence 5'-3' (XXXXWWWWGWWWW)

10
10
11a
11a
11b
12
12
12
13
13
13
14
14
14
14
14
15
15
15
15
15
16
16

Mismatch
type

Position

Binding
fashion

PA tail 5'3'

GTAAC-CCAAAACGGTTTG-CACAC
CTTGT-AAATGTGTAACCC-AAAAC
ATATA-AGTTGCTTGTAAA-TGTGT
AAGCA-ACTTATATAATA-ATACT

3

7855-7867

forward (BS)

CCAA

1

7866-7878

reverse (BS)

ACCC

2

7876-7888

forward (BS)

AGTT

1

7886-8898

forward

ACTT

TGTAG-TTTAGTATTATTA-TATAA
TTATT-GTAGTTTAGTATT-ATTAT
TTATA-TAATAATACTAAA-CTACA
ACTAA-ACTACAATAATTC-ATGT
TAAAC-TACAATAATTCAT-GTATA
TACAT-GAATTATTGTAGT-TTAGT
ACGCC-CTTAGTTTTATAC-ATGAA
ATAAT-TCATGTATAAAAC-TAAGG
TACGC-CCTTAGTTTTATA-CATGA
TCATG-TATAAAACTAAGG-GCGTA
ATTCA-TGTATAAAACTAA-GGGCG
TAAGG-GCGTAACCGAAAT-CGGTT
GGTTG-AACCGAAACCGGT-TAGTA
ACCGG-TTAGTATAAAAGC-AGACA
TGTCT-GCTTTTATACTAA-CCGGT
ATGTC-TGCTTTTATACTA-ACCGG
CCGGT-TAGTATAAAAGCA-GACAT
TGGTG-CATAAAATGTCTG-CTTTT
TTATG-CACCAAAAGAGAA-CTGCA

0

7893-1

reverse (BS)

ATTA

0

7897-5

forward (BS)

GTAG

2

7893-1

reverse

TAAA

3

1-13

forward

ACTA

2

3-15

reverse

TCAT

1

1-13

forward (BS)

GAAT

1

16-28

reverse (BS)

ATAC

1
2

12-24

reverse
forward (BS)

AAAC
CCTT

reverse

AAGG

2

17-19
17-29

2

17-29

reverse

CTAA

2

30-42

forward

GCGT

3
3
3
3

49-61
61-73
61-73
62-74

reverse
forward
reverse (BS)
reverse (BS)

CGGT
TTAG
CTAA
ACTA

3

62-74

forward

TAGT

2

73-85

forward (BS)

CATA

1

86-98

forward

CACC

In Table 4.1, all binding sites of NV1078 on the HPV16 (7662-122) fragment are
shown. The 13 nucleotide binding sequence of the polyamide has been shown with the
associated 5 nucleotide flanking sequences. Blue letters in the DNA sequence indicate
the binding site of TMG, and the highlighted guanine (G) shows an imidazole binding site.
Considering the best fit to the affinity cleavage patterns and the lowest mismatch number
the most probable orientations of the NV1078 polyamide (derived from Table 4.1) are
presented in Table 4.2.
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Table 4.2. Considering the best fit to the affinity cleavage patterns and the lowest
mismatch number the most probable orientations of the NV1078 polyamide (derived from
Table 4.1) are presented.

#

Sequence 5'-3'
(XXXXWWWWGWWWW)

Mismatch
type

Position

Binding fashion

KdHill
(nM)

Ka
(nM-1)

1

ATTAG-GTTAGTTAAAACA-AGCCA

1

7717-7729

reverse (BS)

1.18

0.8

2

ATGCA-ATTAGGTTAGTTA-AAACA

1

7722-7734

reverse (BS)

nd

nd

3

AAATA-TGCAATTAGGTTA-GTTAA

1

7726-7738

forward (BS)

2.59

0.4

5

TGGCA-TAAGGTTTAAACT-TCTAA

1

7748-7760

reverse

2.1

0.5

7a

ATGAA-CAATGTATGACTA-ACCTT

2

7812-7824

reverse (BS)

5.05

0.2

7b

TGTGT-AAAGGTTAGTCAT-ACATT

1

7806-7818

reverse

2.5

0.4

8

TGTTC-ATTTGTAAAACTG-CACAT

0

7828-7840

reverse

1.98

0.5

11a

AAGCA-ACTTATATAATA-ATACT

1

7886-8898

forward

nd

nd

11b

TGTAG-TTTAGTATTATTA-TATAA

0

7893-1

reverse (BS)

1.9

0.5

12

TTATA-TAATAATACTAAA-CTACA

2

7893-1

reverse

2.2

0.5

1

1-13

forward (BS)

3.3

0.3

13

TACAT-GAATTATTGTAGT-TTAGT

The presence of G nucleotide in the tail binding sequence increases the value of
Kd (compare site # 1 with sites # 3, # 8, and # 13). The Kd values not always rise with
the increasing number of mismatch nucleotides as shown in Figure 4.4.

Figure 4.4. Binding affinity of NV1078 on HPV16 LCR sequence
4.4.2 NV1087 polyamide binding sites on 365 bp natural HPV16 (7662-122)
sequence.
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The map ECF3097NV1087(2) Figure 4.5, of DNase I footprinting and affinity
cleavage experimental results of NV1087 polyamide binding sites on 365 bp natural
HPV16 sequence reveal 13 binding sites. The blue box indicates the E1 protein binding
site while E2 binding sites are delineated by green boxes. Multiple cleavage patterns stand
out in the region 7881-17.

Figure 4.5. Binding sites of NV1087 on 365 bp LCR HPV16 fragment. Horizontal
arrows depicting the binding sites are color coded. Black arrow shows perfect binding
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site; Red arrow - single mismatch (mm) site; Purple arrow - double mm; Blue arrow - triple
mm; Green arrow - quadruple mm; Solid arrow - forward fashion of PA binding; Dashes
arrow - reverse fashion of PA binding; Green boxes show E2 binding sites; Red letters
represent the integration peaks; Blue or green letters represent the reference peaks. Red
numbers show the dissociation constant values Kd [nM] presented in Table 4.4. The
yellow background highlights the footprinting regions.

Table 4.3. Binding sites of TMG-HAP, NV1087 on HPV16 (7662-122) fragment.
The 13 nucleotide binding sequence of the polyamide has been shown with the associated
5 nucleotide flanking sequences. Blue letters indicate the TMG binding site and the
highlighted guanine G indicate imidazole binding site
AC
site

DNA Sequence (5'-3')

Mismatch
type

Position

Binding
fashion

PA tail
(5'XXX3')

0a

ACCGC-TGTTAGGCACATA-TTTTT

4

7695-7707

reverse

ATA

2

7704-7726

reverse (BS)

ATG

3

7707-7729

forward

ATT

1

7717-7729

reverse

AAC

forward

ACC

0b
0c
1a

AAACA-AGCCAAAAATATG-TGCCT
CACAT-ATTTTTGGCTTGT-TTTAA
TGGCT-TGTTTTAACTAAC-CTAAT

1b

AACTA-ACCTAATTGCATA-TTTGG

3

7728-7740

1c

CCAAA-TATGCAATTAGGT-TAGTT

3

7728-7740

reverse (BS)

GGT

1'a

TAACC-TAATTGCATATTT-GGCAT

3

7731-7743

forward

TAA

1'b

ATGCC-AAATATGCAATTA-GGTTA

3

7731-7743

reverse (BS)

TTA

reverse (BS)

ACC

2

GCCTT-AGTTGTTTAAACC-TTATA

1

7751-7763

2'a

TTGGC-CTTAGAAGTTTAA-ACCTT

3

7754-7766

forward (BS)

CTT

2'b

AAGGT-TTAAACTTCTAAG-GCCAA

3

7754-7766

reverse

AAG

2'c

CTAAG-GCCAACTAAATGT-CACCC

1

7767-7779

forward

GCC

3a

AATGA-ATGACTAACCTTT-ACATT

4

7806-7818

forward (BS)

ATG

4

7806-7818

reverse

CAT

3

7818-7830

reverse (BS)

GTA

forward

TAC

3a'
3b

TGTGT-AAAGGTTAGTCAT-ACATT
TTACA-AATGAACAATGTA-TGACT

3b'

AGTCA-TACATTGTTCATT-TGTAA

3

7818-7830

4

GTGCA-GTTTTACAAATGA-ACAAT

1

7826-7839

forward (BS)

GTT

5a

GCAAC-TTATATAATAATA-CTAAA

1

7888-7890

forward

TTA

5a'

TTTAG-TATTATTATATAA-GTTGC

1

7888-7890

reverse (BS)

TAA

forward (BS)

TTA

6

TATTA-TTATATAAGTTGC-TTGTA

2

7883-7895

7a

TAGTA-TTATTATATAAGT-TGCTT

0

7886-7898

forward (BS)

TTA

7b

GCAAC-TTATATAATAATA-CTAAA

1

7888-7890

reverse

ATA

7b'

TTTAG-TATTATTATATAA-GTTGC

1

7888-7890

forward (BS)

TAT

8a

TATAT-AATAATACTAAAC-TACAA

1

7894-2

reverse

AAC

1

7894-2

forward (BS)

GTT

8a'

TTGTA-GTTTAGTATTATT-TACAA
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AC
site

DNA Sequence (5'-3')

Mismatch
type

Position

Binding
fashion

PA tail
(5'XXX3')

8b

ATACA-TGAATTATTGTAG-TTTAG

1

2-14

reverse (BS)

TAG

9a

TACAT-GAATTATTGTAGT-TTAGT

1

1-13

forward (BS)

GAA

9b

CCCTT-AGTTTTATACATG-AATTA

1

12-25

reverse (BS)

TGA

10

ATTCA-TGTATAAAACTAA-GGGCG

1

15-27

reverse

TAA

2

61-73

forward

TTA

reverse (BS)

CTA

11a

ACCGG-TTAGTATAAAAGC-AGACA

11b

ATGTC-TGCTTTTATACTA-ACCGG

1

62-74

12a

CGGTT-AGTATAAAAGCAG-ACATT

1

63-75

reverse

CAG

12b

TTTGG-TGCATAAAATGTC-TGCTT

1

75-87

reverse (BS)

GTC

reverse

TGC

forward

GCA

13a

AAAGC-AGACATTTTATGC-ACCAA

1

74-86

13b

TTTAT-GCACCAAAAGAGA-ACTGC

3

85-97

In Table 4.3, all binding sites of NV1087 on the HPV16 (7662-122) fragment are
presented. Considering the best fit to the affinity cleavage patterns and the lowest
mismatch number of the DNA sequence according to the binding rules, the most probable
orientations of the polyamide NV1087 are the ones presented in Table 4.4.
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Table 4.4. The most probable binding sequences of NV1087 on HPV16 (7662122) 365 bp sequence. Blue letters indicate the TMG binding site and the highlighted
guanine G indicate imidazole binding site
AC
site

Sequence 5'-3'
(XXXXWWWWWWWWGW)

Mismatch
type

Position

Binding
fashion

KdHill
(nM)

KaHill
(nM-1)

reverse (BS)
forward

0.76
0.76

1.3
1.3

reverse

1.32

0.8

0b
0c

AAACA-AGCCAAAAATATG-TGCCT
CACAT-ATTTTTGGCTTGT-TTTAA

2
3

1a

TGGCT-TGTTTTAACTAAC-CTAAT

1

7704-7726
7707-7729
7717-7729

1'a

TAACC-TAATTGCATATTT-GGCAT

3

7731-7743

forward

1.32

0.8

3

7731-7743

reverse (BS)

1.32

0.8

1

7751-7763

reverse (BS)

2.79

0.4

3

7754-7766

forward (BS)

3.9

0.3

3

7754-7766

reverse

3.9

0.3

3

7818-7830

reverse (BS)

5.9

0.2

3

7818-7830

forward

5.9

0.2

1

7826-7839

forward (BS)

2.13

0.5

1

7888-7890

forward

3.64

0.3

1

7888-7890

reverse (BS)

3.64

0.3

2

7883-7895

forward (BS)

1.25

0.8

0

7886-7998

forward (BS)

1.12

0.9

1

7888-7890

reverse

1.12

0.9

1

7888-7890

forward (BS)

1.12

0.9

1

7894-2

reverse

nd

nd

1

7894-2

forward (BS)

nd

nd

1

2-14

reverse (BS)

nd

nd

1

1-13

forward (BS)

2.32

0.4

1

12-25

reverse (BS)

2.32

0.4

1

15-27

reverse

1.6

0.6

2

61-73

forward

nd

nd

1

62-74

reverse (BS)

nd

nd

1

63-75

reverse

nd

nd

1

75-87

reverse (BS)

nd

nd

1

74-86

reverse

nd

nd

3

85-97

forward

nd

nd

1'a'
2
2'a
2'a'
3b
3b'
4
5a
5a'
6
7a
7b
7b'
8a
8a'
8b
9a
9b
10
11
11b
12a
12b
13a
13b

ATGCC-AAATATGCAATTA-GGTTA
GCCTT-AGTTGTTTAAACC-TTATA
TTGGC-CTTAGAAGTTTAA-ACCTT
AAGGT-TTAAACTTCTAAG-GCCAA
TTACA-AATGAACAATGTA-TGACT
AGTCA-TACATTGTTCATT-TGTAA
GTGCA-GTTTTACAAATGA-ACAAT
GCAAC-TTATATAATAATA-CTAAA
TTTAG-TATTATTATATAA-GTTGC
TATTA-TTATATAAGTTGC-TTGTA
TAGTA-TTATTATATAAGT-TGCTT
GCAAC-TTATATAATAATA-CTAAA
TTTAG-TATTATTATATAA-GTTGC
TATAT-AATAATACTAAAC-TACAA
TTGTA-GTTTAGTATTATT-TACAA
ATACA-TGAATTATTGTAG-TTTAG
TACAT-GAATTATTGTAGT-TTAGT
CCCTT-AGTTTTATACATG-AATTA
ATTCA-TGTATAAAACTAA-GGGCG
ACCGG-TTAGTATAAAAGC-AGACA
ATGTC-TGCTTTTATACTA-ACCGG
CGGTT-AGTATAAAAGCAG-ACATT
TTTGG-TGCATAAAATGTC-TGCTT
AAAGC-AGACATTTTATGC-ACCAA
TTTAT-GCACCAAAAGAGA-ACTGC

.
The mapping study has shown that the TMG-AHP NV1087 binds with nanomolar
affinity to the expected binding sites (0 mismatches), as well as to other binding sites (one,
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two, three mismatches), with comparable Kd values in agreement with previous findings
for large hairpin polyamides studied by our group.
To determine how the DNA sequences where the polyamide tail binds, can
influence the binding affinity the most probable orientations of the polyamide (Table 4.4),
was taken into consideration. It was found that the presence of G in the tail binding
sequence increases the Kd values. As an example, for forward binding 1 mismatch,
compare AC site 7b’ with 4 and 9a. The Kd value increase from 1.12 nM to 2.13 respective
2.32 at the sites 4 and 9a. The same trend has been observed in the case of reverse
binding. For reverse binding 1 mismatch comparing AC site 7b, 1a, and 10 with 9b, or for
the 3 mismatch sites comparing 1’a’ with 2’a’ and 3b, the Kd values have increased
(Figure 4.6).

Figure 4.6. Binding affinities of NV1087 on HPV16 LCR sequence
The probabilities of polyamide to bind in forward or reverse orientation had also
been analyzed. Binding of NV1087 in forward fashion (Figure 4.7 WebLogo 3.4), have
shown a preference for A and T at the TMG binding site. The polyamide can tolerate
mismatch nucleotides at almost every position. The middle of the fragment, which contains
alternative β/Py is extremely flexible allowing for increased mismatch possibilities.
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Figure 4.7. DNA binding sequence for forward binding of NV1087 on HPV16 LCR
fragment. NV1087 in forward fashion have shown preference for A and T at the TMG
binding site. The middle of the fragment, which contains alternative β/Py is extremely
flexible allowing for increased mismatch possibilities.
Binding of NV1087 in reverse fashion (Figure 4.8 WebLogo 3.4), have shown a
preference for A and T at the TMG binding site. Although the polyamide can tolerate
mismatch nucleotides at almost every position, A and T are preferred through the entire
binding pattern, the only exception being the imidazole binding site which favors G.

Figure 4.8. DNA binding sequence for reverse binding of NV1087 on HPV16 LCR
fragment.
NV1087 in reverse fashion have shown preference for A and T at the TMG binding
site. Although the polyamide can tolerate mismatch nucleotides at almost every position,
A and T are preferred through the entire binding pattern, only exception being the
imidazole binding site.
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4.4.3 Binding sites of NV1078 on the LCR region of HPV18 (7647-157).
Comparison of the binding profiles of NV1078 and NV1042 on the LCR region of
HPV18 (7647-157)
To better understand the differences between TMG-AHP and the leading antiviral
compound NV1042 (PA 25) (5, 10) synthesized by our group, the binding profiles of
NV1078 in the LCR region of HPV18 (7647-157) has been studied. Based on affinity
cleavage data, the binding sites for NV1078 (MAP ECF3109LCR HPV18) had been
compared with the binding sites for NV1042 (CHC1139).
Figure 4.9 illustrates the affinity cleavage sites of NV1078 (A) and NV1042 (B) on
the same DNA sequence. The box shows the binding sites #7, #8, #8’ and #9 of NV1078
HPV18 LCR (Map (ECF3109) corresponding to the sites #16, #17, #18, #19 of NV1042
on the same HPV18 LCR sequence. The underlined region is a G/C reach region where
the presence of polyamides is weak.

Figure 4.9. Sample electropherogram (bottom strand, Hex dye) illustrating the
enhanced affinity cleavage sites of NV1078 (A) comparing with NV1042 (B) on the same
HPV18 LCR DNA sequence. The box shows the binding sites #7, #8, #8’ and #9 (Map
ECF3109) corresponding to the sites #16, #17, #18, #19 (Map NV1042) in the region that
includes E1 and E2 proteins binding sites.
As a general overview, an enhancement at four cleavage sites for TMG polyamide
can be seen. The region in the black box is an A/T reach region (contains about 14% G).
In this area, a highly enhanced cleavage pattern for site #9 compared with #20 and site
#7 compared with #16, can be seen. At the position #9 NV1078, most probably binds in a
1mm forward fashion while NV1042 in 3mm forward fashion. For the 7-16 spot the 0 mm
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reverse binding has clearly enhanced the cleavage pattern comparing with 2mm, or 3 mm
binding possibility of NV1042.
4.5 Discussion
4.5.1 The binding patterns of polyamides to a certain DNA sequence are not
completely predictable
Of the presented data and literature, the hypothesis may be derived that the
NV1078 polyamide can exhibit the following interactions with dsDNA (Figure 10):

Figure 4.10. Hydrogen bonds formed by NV1078 polyamide
The polyamide NV1078 may form hydrogen bonds with the bases in the minor
groove of ds DNA. From a total of 22 intermolecular hydrogen bonds, 19 are formed
between the amide hydrogen atoms and the N3 of adenine or O2 of thymine and cytosine
(hydrogen bond acceptors) that face the minor groove (denoted in red). Furthermore, one
hydrogen bond between N3 of imidazole and a hypothetical C2-NH-H of guanine (red),
and two more hydrogen bounds created by the amide hydrogen’s of the polyamide tail,
according to the bifurcated hydrogen bonds model demonstrated by Dervan, to the N3 of
adenine and/or O2 of thymine and cytosine (120). According to this model the tail of the
AHPs sits in the middle of the minor groove and forms hydrogen bonds with 2 DNA strands
(not marked). An additional third hydrogen bond between TMG and N3 of adenine and/or
O2 of thymine is possible.
Positive charges are present at the polyamide C-terminus (Ta) as well as at the Nterminus (TMG). The positive charge at the N-terminus, unique for this class of
polyamides, facilitates electrostatic interactions between the tetramethylguanidine and the
negatively charged phosphodiester backbone of DNA in addition to hydrogen bond
formation with the base pairs in the minor groove (121). It may be postulated that the
positive charge at the TMG group has a significant role in the enhanced activity of AHPs.
The triad Arg-Pro-Arg at the tail end of an 8 ring polyamide had been shown to compete
successfully for the phosphate backbone and displace the GCN4 protein from the major
groove (122). In analogy with the guanidinium group of arginine, the TMG may be able to
disturb the critical binding of E1 helicase in the major groove.
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Also, the polyamides can establish Van der Waals interactions with the groove
walls: C2-H of adenine favors van der Waals intermolecular contacts with Py H3 protons.
Previous docking studies show that the van der Walls stacking interactions in the minor
groove are more favorable for Py/Py than Py/β configurations (123). Therefore, since
NV1078 incorporates Py/Py units, favorable van der Waals interactions are expected. The
NV1087 incorporate five Py/β units, consequently, this molecule is less prone to take
advantage of van der Walls interactions while bound in the minor groove.
The exocyclic amino group of G will impede PA fitting in the minor groove (121)
since deep penetration of the minor groove is required. The results revealed that although,
the polyamide tolerates mismatch nucleotides well, the presence of the bulky G base is
less preferred at the TMG binding sites (Table 4.2 and 4.4).
Hydrophobic contacts when polyamides bind in the minor groove were not studied
for NV1078 or NV1087 and can be just anticipated. In the case of 8 ring PAs, the
hydrophobic contacts are diminished for Py to β substitution (123). If the same rule applies
to long polyamides, then for NV1087 (two Py/β pairs) the hydrophobic contacts may be
diminished. The NV1078 presents two β/β pairs, therefore stronger hydrophobic contacts
are expected. Since the presence of water weakens electrostatic interactions, it is
expected that NV1087 have enhanced electrostatic interactions with DNA comparing with
NV1078. Positive binding entropies are expected since the release of 4 counterions upon
binding is associated with increased binding entropy.
4.5.2 TMG-AHP polyamides display similar Kd values as other related
antiviral polyamides but significantly lower IC50 and IC90 values, therefore
improved antiviral activity.
During the experimental work, the thermodynamic parameter, equilibrium
dissociation constant (Kd), was calculated for a closed system. In these conditions the
ligand (i.e. TMG-AHP polyamide), and the receptor (i.e. dsDNA) total concentrations were
constant, only the concentration of the free and bound species changes over time until the
system reaches equilibrium. The dissociation constant values do not demonstrate a
severe affinity decrease of the TMG-AHPs at less ideal (two or three mismatches) (Table
4.2, 4.4) sites in agreement with previous findings for large hairpin polyamides studied by
our group (11, 86). Moreover, the Kds have shown insignificant variation comparing with
the Kd values of polyamides less efficient in eliminating the viral load from the same type
of cells (10, 11)

62

Nonetheless, the IC50 and IC90 values were determined in vivo (open system)
and showed dramatic improvement in the ability to eliminate the viral DNA from
keratinocytes comparing with less effective compounds (Table 1.1:

IC50, IC90 for

different PAs).
These apparently contradictory results can be explained if we consider that in an
open system the concentration of the polyamide at the target site can change over time
due to metabolic processes or other elimination mechanisms (e.g. drug resistance). In
natural systems, the effect of a ligand depends not only on the selectivity of the ligand and
its binding properties but also, on the ligand residence time, the amount of time that a
ligand resides on a given receptor after binding (124), at the certain sites. A longer
residence time may translate into a persistent biological effect (125). The IC50 and IC90
values obtained in open biological systems integrate in a better way the factors that
contribute to the overall response of the cells to the TMG-AHP action(s).
4.5.3 Viral DNA is capable of adjusting its parameters (intrinsic bending and
minor groove width) to allow binding of TMG-AH polyamides. By interfering with the
formation of E1/E2 complex TMG-AHPs block viral DNA synthesis by obstructing the
replication process at the start.
The early expressed viral proteins E1 and E2 are essential and sufficient for
initiation of HPV DNA replication (126, 127). All other factors required for replication of
episomal DNA are obtained from the host cell. E1 protein contains a DNA- binding domain
(DBD) and an ATP-ase / helicase domain (128). E1 binds DNA, as a dimer through its
DBD, along with E2 protein at the viral origin of replication (126) leading to a final double
hexameric helicase, assembled by E2 protein.
The ability of the E1DBD to bind DNA as a dimer is required for the assembly of
E1 as a replication- competent double-hexamer (DH) at the ORI (126). Also, the assembly
recruits cellular replication factors that will replicate the viral genome. Previous studies
showed that polyamides that overlap completely (or partially) with the protein binding sites
are effective at displacing the DNA binding protein by impeding essential amino acid-base
pair contacts(129). In the cited case, when tandem polyamide binds in the minor-groove
the intrinsic bending of the DNA will be altered, therefore E2 DBD won’t be able to bind in
the major groove of the DNA (129).
From side by side comparison of the AC binding profiles of NV1087 and NV1078
on the same HPV 16 DNA (Figure 4.10) it was concluded that the TMG-AHP polyamides
have a preferred binding region where AC cleavage patterns stand out (7880-30). Both
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polyamides bind in a cluster mode on the ORI of HPV16 that includes the sites of E1 and
E2 proteins, sites that are critical in the process of the initiation of DNA replication. The
box in Figure 4.11 shows a cluster of polyamide binding sites.

Figure 4.11. Mapping studies performed with NV1078 and NV1087 polyamides
on a 365 bp HPV16 DNA sequence indicate that the polyamides bind with high affinity in
the region adjacent and overlapping with the E1BS.The preferred binding sites where
AC cleavage patterns stand out are presented in box.
Since polyamide NV1078 is even more active against HPV18 than HPV16 its
binding profile on HPV18 LCR (7647-157) sequence was also studied. Although the
polyamide binds in many different sites, it has a noticeable preference for the sequence
(7841-43). Moreover, as a result of the comparison of the binding profiles of a TMG-AHP
polyamide, NV1078, and the leading antiviral compound PA25 (NV1042), the enhanced
affinity cleavage region of NV1078 Figure 4.9 convinces us that NV1078 presents
superior binding proprieties regarding HPV episomes than NV1042.
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4.6 Conclusions
Throughout our efforts to discover compounds useful in eliminating HPV, during
the maintenance stage of its life cycle, TMG- AHPs were developed and showed potential
as possible (antiviral compounds) drugs for the treatment of preexisting and future HPV
infections.
The antiviral activity of the compounds was demonstrated by proving the decrease
of viral DNA levels in human keratinocytes in cells that maintain HPV16, HPV18, and
HPV31 episomal HPV DNA, without integration of viral DNA (T. Edwards, C. Fischer).
Two, NV1078 and NV1087, asymmetric TMG polyamides were found to have excellent
antiviral activity against all three HPV strains HPV16, HPV18, and HPV31. Similar activity
against different HPV strains is a unique property, (only one more compound the NV1087
isomer, NV1111, was found to have similar proprieties) most of our compounds distinguish
between different strains.
Evidence from biophysical studies supported the primary step of the underlying
mechanism of action. The large polyamides NV1087 and NV1078, which recognize 13
base pairs, tolerate well one, two, and three mismatch binding sites. The high tolerance
of mismatched sequences does not affect the biological activity, suggesting that other
factors besides sequence specificity, such as the presence of TMG group and possibly
the residence time, may be crucial for explaining the unique antiviral proprieties of the
TMG-AHPs.
Although, the role of tetramethylguanidine groups in the cellular and nuclear
uptake of TMG-AHPs are not completely understood, our findings are in concordance with
previous studies that have shown that guanidilated compounds improve the ability of
compounds for cellular uptake (130, 131).
Based on the collected data, it may be concluded that the binding of TMG-AHPs
in a cluster in the region adjacent and overlapping with the E1, E2 binding sites has a
significant contribution to the overall biological activity.
The intensive binding in the minor groove of dsDNA (sequence 7880-30 of HPV16
and sequence 7841-43 of HPV18) of TMG-AHPs structurally alter the dsDNA. The
required adjustments of the DNA to allow binding may cause the inability of E1/E2 to
assemble, as a replication competent double-hexamer (DH) at the ORI, obstructing the
replication process at the start.
Moreover, it is rational to predict that the intensive binding in the region mentioned
above may cause ssDNA exposure or double strand breaks within HPV DNA (6) and the
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activation of DNA damage response (DDR) pathways (6). Multiple binding sites induce
DNA nicks which activates ATR. Our findings complement the notion that the PA binding
to negatively supercoiled HPV episomes activate the DNA damage response (DDR)
pathways (6). Activation of DDR genes eliminates the viral episomes without having
substantial effects on cell growth or apoptosis (6).
The elimination of viral DNA during the maintenance stage it is an effective strategy
for the development of antiviral compounds. TMG-AHPs have the potential to be useful
for the treatment of preexisting and future HPV infections.
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Chapter 5
Differential DDR Gene Expression Profile of W12E Cells After
Treatment with Active Anti-HPV Hairpin Polyamides
5.1 Abstract
Human papillomaviruses (HPV) infect the basal layer of the epithelium. DNA
damage response (DDR) machinery can recognize viral DNA and replicating viral genetic
material as foreign DNA. Low levels of DDR components are expressed in episome
bearing cells. Once DDR senses DNA damage, it will recruit an elaborate network of
transducers and effectors to repair the damage or initiate apoptosis. In theory viral
propagation could be restricted. However, HPV developed ways to take advantage of the
DDR machinery and coexist with it. Moreover, HPV uses DDR elements for its replication.
It had been shown that in addition to induction of DDR genes by HPV, anti-HPV
polyamide treatment of episome-bearing cells also causes the alteration of some DDR
gene expression levels (6, 117). Gene products that act as both enhancers and repressors
of anti-HPV activity of polyamide PA25 were identified (6). The goal of the present study
is to compare (and find the common features of) the effects of the polyamides NV1078
and NV1042 on genome regulation, using NV1011 as a control like in the previous study
(6).
The polyamides’ effects on DDR gene expression were analyzed after treatment
of W12E cells with the polyamides mentioned above. W12E cells are undifferentiated
cells, harboring 100-500 viral episomes per cell. Therefore, they were used as model for
gene expression studies of cells mimicking the maintenance phase of the HPV lifecycle.
Total RNA was extracted and converted to cDNA. To measure the transcript abundance,
seven DDR genes and five reference (housekeeping) genes were analyzed in parallel.
The goal of this project was to have an initial feedback before completing analysis
of RNASeq data on polyamide effects. QPCR studies monitored expression of the seven
DDR genes (Table 5). These genes are the Transducers (Ataxia-telangiectasia mutated
kinase, ATM and Ataxia telangiectasia and Rad3-related protein, ATR (8)) and first line
effectors (CHEK1, CHEK2) in the homologous recombination (HR) pathway. Also, RAD1,
RAD9A and TP53 were included in the study (Table 5.5 and Chapter 1).
The gene expression analysis is expected to lead to the identification of genes
relevant to the polyamide mechanism of action and provide insight into the complex
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regulatory DDR networks. Additional QPCR work will be done to follow up and test the
RNASeq results.
5.2 Introduction. DDR response in cells infected with HPV16
The virus HPV has a complex relationship with the infected host cells. In its intricate
association with the DDR, the virus has to accomplish two important tasks to replicate in
the host cell. First, the virus has to evade the DDR, which senses foreign DNA and DNAbound viral proteins as a threat to genomic integrity. Moreover, the virus has to use
elements of the DDR to complete its own deficient transcriptional machinery.
Suppression of DNA damage response is achieved by viral proteins E6 and E7,
which act as direct or indirect antagonists of different DDR components. E6 and E7 interact
with DDR components in addition to their other functions. The principal function of E6 and
E7 proteins is to maintain the keratinocytes in a proliferative state. This function is
achieved in part when E7 inactivates Retinoblastoma protein (pRB) and E6 targets the
protein p53 for proteasomal degradation, therefore preventing the cell from undergoing
apoptosis. The two oncogenic viral proteins E6 and E7 work cooperatively to avoid
downstream signaling, therefore undermining the DDR response in undifferentiated and
differentiated host cells (9, 48, 113, 114).
Among numerous functions of viral oncogene E7 (see Introduction, Chapter 1 (1))
is its ability to abrogate the ATM-ATR pathway-induced checkpoints. E7 causes the
degradation on claspin, a key regulator of ATR-CHK1 pathway, therefore promoting
mitotic entry in the presence of foreign DNA (1).
Similarly to E7, E6 creates interactions with a multitude of cellular proteins. Among
those, the relation with p53 is important from a DDR point of view, since activation of the
ATM and ATR signaling cascades leads to phosphorylation of the p53 tumor protein
(Figure 1). The oncoprotein E6 antagonizes the function of p53, forming an E6-E6
associated protein (E6AP)-p53 and targeting p53 for proteasomal degradation (132). In
this way, E6 eliminates the p53-dependent apoptosis (1). Furthermore, E6 interferes with
p53 at a genomic level. The interaction of E6 with histone acetyltransferases p300, CREB
binding protein, and ADA3 prevents p53 acetylation, and through this, inhibits the
transcription of p53 responsive genes (1).
Manipulation of DDR promotes the viral lifecycle. HPV utilizes both the ATM (9,
19) and ATR (5, 133) pathway for replication and vegetative amplification. The ATM
pathway components have been shown to be critical regulators of HPV in the amplification
phase of differentiated keratinocytes. Nevertheless, the pathway is activated in
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undifferentiated cells as well (9). Multiple viral proteins can activate ATM pathway and
work independently or cooperatively to promote viral replication as shown in Table5.1.
Table 5.1. Viral proteins that activate the DDR pathways to replicate the viral genome by taking
advantage of host repair proteins.
Homologus Recombination
Pathway, HRP
Viral protein
Effect on cells
ATM
E1 helicase
ds DNA breaks
Chromatin remodeling;
E2/ BRD4
replication centers inducer
G2/M arrest; CHK1, CHK2
E7
activation; STAT-5 activation
ATR

E1

CHK1 activation

Viral helicase E1 is the major activator of ATM in undifferentiated cells, expressing
a complete viral (HPV11, 16, 18, 31) genome (34). Nuclear accumulation of E1, leading
to nonspecific DNA unwinding, may result in the induction of undesired DNA breaks in the
host genome (133), and consequently, induction of ATM pathways and arrests in the S
phase, allowing viral replication. E1 helicase activity is attenuated by complex formation
with E2 or by nuclear export (34). Both events, complex formation and nuclear export, are
paramount, as they will keep low levels of E1 in undifferentiated cells, desirable to avoid
genomic instability generated by ds DNA breaks which could favor integration of the viral
genome (34).
The E2 viral protein ameliorates E1 effects but also activates the ATM pathway
following an entirely different mechanism. E2 binds to BRD4, which tethers the episomes
(HPV 16, 18) to the host chromatin (35) to ensure replication in the initial amplification
phase and the maintenance phase. This tethering mechanism ensures that the low copy
of the viral genome is retained in the nucleus, and it is partitioned to daughter cells. BRD4
interacts with chromatin and has a significant role in the formation of the viral replication
centers(36, 41). Therefore, E2/BRD4 complex is an intermediate component that attracts
cellular proteins to viral replication centers to initiate the replication of viral DNA. ATM
homologous recombination elements pATM, pH2AX, and pNBS1 are colocalized with
BRD4/E2 proteins in the replication centers (43). Replication centers were spotted and
detected by confocal imaging in differentiated and undifferentiated (HFK-HPV16E1/E2)
cells as well (43).
Viral proteins, in particular oncoproteins E6 and E7, which drive an aberrant
proliferation of the cells, provoke a DDR response used by HPV for viral replication. The
viral E7 protein has been shown to activate the ATM pathway (1) and its downstream
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effector CHK2 in differentiated as well as undifferentiated cells harboring the HPV31 virus
(9). Phosphorylation of ATM and its downstream effector CHK2, as well as CHK1, was
also observed in cells harboring HPV18 (134).
Activation of the ATM response in cells induces a G2/M arrest that provides an
environment favorable to productive viral replication (9). It is important to notice that NBS1
(Nijmegen breakage syndrome 1, also known as nibrin), part of the Mre11–Rad50–Nbs1
MRN sensor complex which promotes monomerization and autophosphorylation of the
ATM kinase, is only activated in differentiated cells (1). It was also shown that the
formation of viral replication centers in differentiating cells is dependent upon ATM activity,
for pATM, pCHK2, pNBS1, and γH2AX are present in the amplification centers (9).
In addition, E7 forms complexes with phosphorylated ATM proteins (113), but not
the unphosphorylated form of ATM (9). This interaction may allow ATM to recognize novel
substrates (9). In the same paper, it was demonstrated that although the ATM pathway is
activated in undifferentiated cells, it is not essential for stable maintenance of viral genome
(9). ATM activation is necessary for viral genome amplification in differentiating cells (9).
E7 also activates the cytosolic transcription factor STAT-5 (15). The
phosphorylated STAT-5 induces increased levels of PPARγ (a nuclear transcriptional
factor) in HPV31 positive cells, which (possibly with the help of additional intermediary
proteins) activates the ATM DNA damage pathway (8) leading to genome amplification
(15).
Hitherto, it is unclear how ATM factors specifically contribute to replication. It was
hypothesized that the primary function of ATM factors is to help resolve concatemers of
viral DNA, or that viral replication is mediated by DNA repair polymerases and ligases
(15).
Complementing ATM factors, HPV also utilizes the ATR pathway for replication
(133) (5, 6). Using U2OS cells transfected with the E1 protein expression constructs,
HPV16 and HPV18 were shown to activate the phosphorylation of ATR and CHK1 in
undifferentiated and differentiated cells, and members of the ATR pathway localized to
HPV replication centers (133).
Inhibition of ATR pathway components reduces the number of HPV episomes that
are stably maintained in W12 keratinocyte cell lines, suggesting a role of the ATR pathway
in HPV16 replication in undifferentiated cells (5, 6).
Moreover, the previous DDR gene study (6) showed that 11 genes were employed
by the virus to maintain the episome levels in cells in natural conditions during the
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maintenance phase (6). Among those eleven genes that augment the HPV16 episome
levels in W12E cells, three are members of the DDR pathways, ATM, RTEL1 (an HR
suppressor), and RUVBL2 (a helicase essential for DBS repair).
The ATM transducer and CHEK2 effector play an important stabilizing role for the
HPV episome that does not require kinase activity (5, 6); the ATR transducer and CHEK1
effector stabilize the HPV, lessening the replication fork effects generated by E1 and host
replication factors (which is thought to be intrinsically unstable (117).
Large PA’s alter the DDR response initiated by HPV episomes
As shown, the HPV episomal DNA by itself mediates a DDR response in cells
infected by the virus not just in the amplification phase, but also in the maintenance phase.
The extent of DDR involvement is directly proportional to the HPV episome numbers
present in cells.
Previous studies have shown that the large PA25 induces a DDR response in cells
infected with the HPV virus (5, 6, 117). The significant viral loss registered when infected
cells were treated with an active polyamide is a consequence of the degradation of the
viral episome, not just the inhibition of viral DNA replication (117). No such response was
observed when cells that contained already integrated HPV were treated with the same
polyamide (117). Also, when treated with PA 25 the viral episome from infected cells was
cleared without integration in the host chromosomes (6, 117). Simultaneously, DDR genes
were upregulated or downregulated as a result of PA25 binding in the minor groove of
episomal DNA (6, 117).
The activation of DDR pathways and the use of their elements for viral
maintenance was evidenced in W12E cells using siRNA-mediated knockdown of the DDR
genes. Knockdown or inhibition of the transducer genes ATM and ATR and other proteins
in the DDR pathway lead to the decrease of episome numbers. A drastic 40%–50%
reduction in the HPV16 copy number in W12 cells was registered (5, 6, 8).
The degradation of the viral episome was supported by the Aphidicolin action on
viral episomes. Aphidicolin, a selective α-polymerase inhibitor with antimitotic proprieties,
is known to activate a DDR (ATR) response and cause significant episome loss when
used for the treatment of cells infected with viral episomes (5). Meanwhile, no significant
changes were registered when Aphidicolin was used on infected cells already treated with
polyamides. The episomes already degraded by polyamides are uninvolved in the
response to Aphidicolin treatment. The goal of the present study is to find the similarities
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and differences in the way of action of the PA’s presented in Table 5.2 by the RT-QPCR
method.
Table 2. Polyamides used in RT-qPCR studies. The IC50 and IC90 values measured for W12E
cells were determined by T. G. Edwards in the Fisher lab, unpublished data.

PA

PA sequence

IC50 [µM]

IC90 [µM]

NV1011 (PA11)

ImPPIm-γ-PPPP-β-Dp

NOT ACTIVE

NOT ACTIVE

NV1042 (PA25)

ImPP-β-PPIm-β-PP-γ-PPβPPPβPPP-β-Ta

0.036

0.351

NV1078 (TMG-AHP)

TMG-PβPPIm-β-PP-γ-PP-β-PPP-β-PPP-β-Ta

0.046

0.307

5.3 Materials and Methods
5.3.1 Cell Culture; W12E Keratinocyte Cells (clone #20850)
The Keratinocyte cell line (W12E clone #20850) containing HPV16 genomes as
episomes (10, 135, 136) was maintained in monolayers in E-media (3 parts DMEM with
high glucose, and one part F12 media) in the presence of mitomycin C treated 3T3
fibroblast feeder cells.
The 3T3 cell line is a fibroblast cell culture (ATCC NIH/3T3) established from the
disaggregated tissue of an embryonic albino Swiss mouse. The 3T3 feeder cells used in
this experiment were received from the lab of Paul Lambert on 25 Dec 2009, and were
stored in liquid nitrogen (J23T3 GH2012). In culture, 3T3 cells can form confluent
monolayers with contact inhibited cell motility. The 3T3 cells could grow indefinitely and
do not instigate tumor growth. The 3T3 fibroblasts (Figure 1) are used as feeder cells for
keratinocyte cells (W12E) because they secrete growth factors favorable for keratinocytes.
Thus, they enhance the growth of human keratinocytes and shorten the cultivation time of
said keratinocytes. The 3T3 fibroblasts have been maintained in a monolayer culture to
80% confluence in growth media (DMEMF10 - Dulbecco's Modified Eagle's Medium
̊ , 5%
supplemented with 10% BCS and 1% pen-strep). The cells were grown in a 37 C
CO2, humidified incubator and passaged to 1:10 every three days based on previously
published protocols (137) (Cell culture, 3T3 Protocol: ECF3133). The 3T3 cells were
incubated with mitomycin for 2 hours at 37°C in a 5% CO2 humidifier incubator.
Mitomycin C from Streptomyces caespitosus, which inhibits the proliferation of 3T3
cells, was added to the 3T3 cells before being used as feeders for keratinocytes, to a final
concentration of 8 µg/mL (200 µL 50X mitomycin C per 10 mL E-medium (138). Mitomycin
C (Figure 1) treatment was utilized to stop the division of the 3T3 cells. Mitomycin C reacts
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covalently with DNA, crosslinking complementary strands and inhibiting DNA replication
(137).

Figure 5.1. Mitomycin C structure
The W12 cell line which is representative of a premalignant HPV16 induced tumor
was derived from a low-grade cervical lesion and retains the HPV16 genome as an
episome (139). W12E cells contains a frameshift mutation in the E1 gene (140) with the
accession number on GenBank as AF125673.The W12E keratinocyte cells (Figure 1.B)
harbor extrachromosomal HPV16 genomes with HPV16 copy numbers ranging from 300
to 500 copies per cell (5, 10, 135). In the basal layer, the initial stage of infection, the
episome number is considered to have little copy number variation, and it is considered
stable.
The W12E clone #20850 cells, maintained at early passage (from P #13 to P #17)
have been cultured in monolayers on top of a mitomycin treated 3T3 feeder layer. Clone
20863 W12E cells are known to be differentiated keratinocytes (141)
High passage number was avoided since W12 cells grown in long-term cultures
have the ability to differentiate (142). The cells were maintained at 37 ̊C in a humidifier
incubator with 5% CO2 in a medium consisting of E-media (3 parts DMEM w/ high glucose,
pyruvate and 1 part F12 media) supplemented with 0.4 μg/ml Hydrocortisone, 0.1 nM or
10 ng/ml Cholera toxin, 5 μg/ml Insulin, 24 μg/ml Adenine, 10 ng/ml Epidermal Growth
Factor,

5

µg/ml

Transferrin,

20

pM

3,3,5-Triiodo-thyronine

(T3),

1%

Penicillin/Streptomycin, and 5% Fetal Bovine Serum (5). The media components were
filtered using syringe filters (Millex-GP 0.22 µm) and aliquoted. The prepared E-Complete
and E-Incomplete (contains no EGF) cell media were sterilized using Nalgene 0.2 PES
filters. The E-Incomplete media was used for culturing keratinocyte and 3T3 feeder cells
the first day after passaging. The W12E cells have been passaged at 70% confluence
using a split ratio of 1:10 (5) (Epithelial cell culture protocol: ECF3134).
The W12E (1x105) cells were seeded on the top of 1x105 mitomycin treated J23T3
fibroblast cells in 6 well plates (Sigma-Aldrich, CLS3516-50EA). The working volume of a
six-well plate is 1.9-2.9 ml, the growth area is 9.5 cm2, and the expected cell yield varies
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between 9.5 x 105 to 106 cells. The cells were plated at a density of 1x105 cells/ml. Table
5.3 includes the passage numbers of the cells used for obtaining the biological replicates.
Table 5.3. The W12E and the 3T3 passage numbers used for obtaining 5 series of
biological replicates. Also, the RNA extraction dates and the notebook page numbers
are included.
W12E cells
J23T3 cells
Set I/Set II
Total RNA
extraction Set
I of PAs
Total RNA
extraction
Set II of PAs

Series 1

Series 2

Series 3

Series 4

Series 5

P13
P22/P18

P14
P23/P19

P15
P24/P20

P16*
P25/P21

P17
P26/P22

11/7/15
ECF3153

11/10/15
ECF3157

11/13/15
ECF3165

11/16/15
ECF3168

11/19/15
ECF3171

12/1/15
ECF4007

12/5/15
ECF4011

12/8/15
ECF4015

12/11/16
ECF4021

12/14/15
ECF4022

Set I polyamides refers to polyamides NV1078, NV1087(6102A), NV1042
(KJK6006) (6) NV1028 (GDH1130) NV1111(KA2092) . Set II polyamides refer to NV1011
(KJK1083D 88%), NV1113(KJK6169), and NV1115 (KJK6170)
*According to Garner-Hamrick (135) P16 W12E will have about 1273 HPV copies
per cell, while according to Edwards (5) P16 will have 300-500 copies per cell.

311.86μm x 311.86μm
311.86μm
311.86μm
Figure 5.2. Confocal image
of livexW12E
cells incubated with DRAQ5 for 10 min. λ=
639 nm, 40X, (ECF 1130.6). The W12E are polygonal in shape with relatively regular
dimensions and grow attached to a substrate in discrete patches. The Keratinocyte W12E
cells form clusters among 3T3 cells. The image was acquired with a Zeiss LSM 700 laser
scanning confocal microscope (LSCM).
The cells were plated in 6 well plates at a seeding density of 1x105 J23T3 cells and
1x105 W12E cells in 2 ml E-media. The number of cells was determined using a Nexcelom
Bioscience Cellometer Auto T4 instrument (cell counting chambers plates SD100).
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The W12E cells are identified as biohazardous agents as representatives of Risk
Group 2 (RG2). The detailed workflow of the cell culture experiments was submitted for
approval to the Institutional Biosafety Committee. The experimental work was done in
compliance with standards and regulations according to NIH guidance biosafety level 2
(BL2) (143).
5.3.2

Treatment of the cells with active polyamides

The W12E cells have been treated with 7 active polyamides, an inactive polyamide as
a negative control (Table 5.2), and 0.1% DMSO vehicle as control. The cells were
incubated with polyamides on day two for 24 hours. It was assumed that the selected PA’s
follow the same pathway during uptake within the cells (see introduction).
The IC50 and IC90 values (Chapter 1) which show the effectiveness of PAs clearing the
HPV episomes from infected cells were used as guidance to decide the polyamide
concentration. The cells had been treated with 0.1 μM PA for 24 h.
Lyophilized aliquots of PAs were resuspended in 20 µL sterile DMSO (100µM). 2 µL of
polyamides were added to 1998 µL of E Complete Media on the second day of culturing
the cells. The cells were incubated for another day (24 hours precisely). In this way, the
final polyamide concentration in the media was 0.1 µM in 0.1% DMSO. The lyophilization
solvent was composed of 50% (water + 0.1% TFA), and 50% (Acetonitrile + 0.1%TFA).
5.3.3

Extraction of total RNA

RNA extraction optimization. Before collecting the RNA used for subsequent
experiments, experimental trials were used to decide the proper incubation volume and
the protocol steps for harvesting the cells and extracting the RNA. It was found that 300xg
centrifugation speed for 5 minutes works well when using either an Eppendorf 5424R, a
FA-45-24-11, an Eppendorf mini spin, a F-45-12-11, or a Sorval ST16R centrifuge for cell
pellet collection. When using QIAshredder and RNeasy spin columns, 12,500g
centrifugation speed was used. It was found that 2 ml of cell suspension containing 2.6 x
105 cells yielded an RNA concentration of 0.9 µg/ml. This concentration was found proper
for downstream experiments. Therefore, the cells were plated in 6 well plates at seeding
density of 1x105 J23T3 cells and 1x105 W12E cells in 2 ml E-media. The RNA
concentration was measured using Epoch Microplate BioTek spectrophotometer
equipped with Gen 5 software. Based on absorbance values, the concentration of RNA
was calculated based on the equation
CRNA = 44ng/µL X A260 X dilution factor
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RNeasy procedure. The total RNA (viral and genomic) was extracted following
the RNeasy Plus Mini Kit, Qiagen 74134, protocol (ECF4008). Through the RNeasy
method, all RNA molecules longer than 200 nucleotides were purified. The process
provides enrichment for messenger RNA (mRNA) since most RNAs shorter than 200
nucleotides, such as ribosomal RNA (rRNA, makes up ribosomes along with other
proteins), and transfer RNA (carries amino acids to mRNA to form polypeptides) are
excluded from the purified pool. The goal of the purification process was to capture the
mRNA which carries the genetic information of DNA from the nucleus to the cytoplasm for
protein synthesis.
Cells grown in a monolayer seeded at a density of 1x105 J23T3 cells and 1x105
W12E cells in 2 ml E-media were trypsinized and resuspended in medium containing fetal
bovine serum to inactivate the trypsin. The cells were collected as a cell pellet before lysis.
To improve the RNA yield, complete removal of the cell-culture medium was necessary.
The culture media can inhibit lysis and also dilute the lysate, disturbing the binding of RNA
to the RNeasy membrane.
Cells were disrupted by adding Buffer RLT, a guanidine-thiocyanate–containing
buffer. Guanidine thiocyanate (GATC) is an extremely potent chaotropic agent which
quickly denatures macromolecules and inactivates nucleases. GATC disrupts any
hydrophilic bonds, therefore lysing the cell membrane, linearizing nucleic acids, and at the
same time completely destabilizing RNAses. In the lysis buffer, RNA is perfectly
protected. The Qiagen RLT buffer composition is confidential, but usually lysis buffers
contain guanidine thiocyanate (5M-10M) which is dissolved in Tris-HCl (0.1 M) + 0.5M
EDTA + Tween-20 or Triton X-100.
To ensure total inactivation of RNases, beta-mercaptoethanol (β-ME), 1 µL to the
1 ml buffer, was also added to the RTL buffer. An additional step for homogenization of
the lysate with QIAshredder, Qiagen 79654 spin columns was introduced. After
homogenization, the lysates were transferred to a gDNA eliminator spin column and
centrifuged at high speed (12,500g).
To provide appropriate binding conditions to the column membrane, ethanol was
added to the flow-through, and the samples were applied to an RNeasy Mini spin column.
The RNA binds to the positively charged columns’ (silica, porous glass) membrane in the
presence of the high salt concentration. Contaminants were efficiently washed away using
Buffer RW1 (contains guanidine salt, which removes carbohydrates) and Buffer RPE
(wash buffer containing ethanol).
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The total RNA bonded to the column membrane was eluted with 60 µL of RNasefree water. The RNA samples are stored at -80 °C as aliquots of: 20 µL (for further
RNASeq experiments), 20 µL (for further QPCR experiments), 17 µL (for DDR-QPCR),
and 3 µL (for quality and quantity determination, RIN). The first set of samples was used
for TruSeq library preparation (Chapter 6), the second set was stored for RNASeq
validation experiments (after bioinformatics will communicate us the whole spectrum of
genes that were altered), and the third was used to analyze the polyamide’s effects on
DDR gene expressions for immediate feedback.
5.3.3.1 The quality of total RNA
Assessing the quality of starting material for downstream experiments is very
important since high quality RNA is needed to correctly assign the mRNA expression
levels. The quality and quantity of the total RNA was determined using the BioAnalyzer
Agilent 2100 instrument in compliance with Agilent RNA 6000 NanoKit protocol (50671511).
The RNA integrity of total RNA samples purified from W12E cells bearing HPV16
episomes, was tested using 1 µL of the total RNA.

In every well of the chip of

interconnected microchannels, 1 µL of total RNA was added to a support of 5 µL of geldye. The nucleotide fragments have been separated, as they were driven through
electrophoretically and the results were registered as an electrophoretic trace.
The electrophoretic trace (electropherogram) provided the RNA integrity number
(RIN), the total RNA concentration of the samples, and the ribosomal ratios. RNA integrity
number (RIN) is a software tool that estimates the integrity of the RNA samples and
assigns an integrity number to eukaryote tRNA samples when the concentrations of the
samples are > 25 ng/µL (Agilent Technologies, Palo Alto, CA, USA). To estimate the RIN,
the entire electrophoretic trace is considered, not just the ribosomal bands ratio. The
ribosomal ratios are frequently used to determine the integrity of the RNA samples. If
28S/18S > 2 or higher, the 28S/18S ratio is an indication that the purified RNA is intact
and hasn't degraded.
The electropherograms obtained after the extraction of the RNA which allow for visual
inspection of RNA integrity are provided in the supplementary material. The RIN scores
and the concentration of the samples are provided in Table 5.4.
5.3.4 Reverse Transcription of RNA
After treatment with polyamides (0.1 µM, 24 h in cell growth media), the W12E total
RNA was extracted according to the RNeasy procedure and converted to complementary
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DNA (cDNA). cDNA was synthesized from 1 µg of DNA-free total RNA in a 20 µL reaction
volume using a Maxima First Strand cDNA Synthesis Kit for Reverse Transcription
qualitative PCR (RT-qPCR) (K1641 Thermo Fischer Scientific). The kit employs the
Maxima Reverse Transcriptase Enzyme, an advanced enzyme derived by in vitro
evolution of M-MuLV RT, and oligo (dT)18 and random hexamer primers to prime synthesis
of first strand cDNA. The oligo (dT)18 is specific for mRNA and initiate reverse transcription
at the 3’ end of the transcript. Random primers are used only in two-step qRT-PCR
reactions. The negative control, reverse transcriptase minus (RT-), was performed to
evaluate for genomic DNA contamination of the RNA sample. For every biological
replicate, 1µg of total RNA was used for reverse transcription.
Table 5.4. RIN, volumes and concentrations of total RNA samples used for reverse
transcription corresponding to 1 µg sample.

PA-Replicate
NV1078-1
NV1087-1
NV1042-1
NV1028-1
NV1111-1
0.1%DMSO-1
NV1078-2
NV1087-2
NV1042-2
NV1028-2
NV1111-2
0.1%DMSO-2
NV1078-3
NV1087-3
NV1042-3
NV1028-3
NV1111-3
0.1%DMSO-3
NV1078-4
NV1087-4
NV1042-4
NV1028-4
NV1111-4
0.1%DMSO-4
NV1078-5
NV1087-5
NV1042-5

RIN*
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10

Total RNA (ng/µL) tRNA µg (17μL) ͣ
314
644
352
192
330
275
369
690
521
472
335
542
127
118
99
92
93
122
239
307
252
278
277
301
330
308
335

5.3
10.9
6.0
3.3
5.6
4.7
6.3
11.7
8.9
8.0
5.7
9.2
2.2
2.0
1.7
1.6
1.6
2.1
4.1
5.2
4.3
4.7
4.7
5.1
5.6
5.2
5.7
78

tRNA(μL)
3.2
1.6
2.8
5.2
3.0
3.6
2.7
1.4
1.9
2.1
3.0
1.8
7.9
8.5
10.1
10.9
10.8
8.2
4.2
3.3
4.0
3.6
3.6
3.3
3.0
3.2
3.0

PA-Replicate

RIN*

Total RNA (ng/µL) tRNA µg (17μL) ͣ

NV1028-5
10
155
NV1111-5
10
394
0.1%DMSO-5
10
278
NV1011-1
10
134
NV1113-1
9.9
126
NV1115-1
10
219
NV1011-2
10
232
NV1113-2
10
110
NV1115-2
10
166
NV1011-3
10
87
NV1113-3
10
82
NV1115-3
10
51
NV1011-4
10
179
NV1113-4
10
112
NV1115-4
10
18
NV1011-5
10
179
NV1113-5
10
170
NV1115-5
10
136
*Bioanalyzer data from ECF4030
ͣTotal RNA aliquot for DDR qPCR experiments

2.6
6.7
4.7
2.3
2.1
3.7
3.9
1.9
2.8
1.5
1.4
0.9
3.0
1.9
0.3
3.0
2.9
2.3

tRNA(μL)
6.5
2.5
3.6
7.5
7.9
4.6
4.3
9.1
6.0
11.5
12.2
19.6
5.6
8.9
55.6
5.6
5.9
7.4

The reaction components were incubated for 10 min at 25 °C followed by 15 min
at 50 °C. Reverse transcription of RNA extracted from W12E cells after treatment with
polyamides was terminated at 85 °C (5 min) in agreement with the K1641 protocol. cDNA
was stored at -20 °C for a week or -80 °C for further experiments.
5.3.5 Real Time - Quantitative Polymerase Chain Reaction (RT-qPCR).
Relative quantification method. Normalization against reference genes
To assess the gene-specific transcription levels, the first strand cDNA was primed
with specific primers (DNA Repair II Pathway PCR array, HDRL-II, RealTimePrimer) which
hybridized to the reference genes or the chosen target DDR genes. The control genes,
further named reference gene primers, were supplied along with the Human DNA Repair
Primer Library II (RealTimePrimer).
Real-time quantitative PCR is a fluorescent-based method which permits the
detection of small amounts of DNA in a large variety of samples. Single-stranded cDNA
was transformed into dsDNA in the presence of Maxima SYBR Green ROX qPCR Master
Mix (Fermentas, K0221). The initial amplicon amount was measured with a BioRad CFX96
Real-Time System. The quantitative PCR (q-PCR) reaction was performed using a two79

step cycling protocol, following cycling conditions: 1X 95 °C for 10 min (initial activation of
enzyme Maxima Hot) followed by 40 cycles of 95 °C for 10 sec (denaturation), 58 °C for
45 sec (annealing and extension) (6). Hard shell PCR plates (HSP9601 Bio-Rad) were
sealed with PCR Microseal “B” film (MSB1001).
The master mix used included Maxima Hot Start Taq DNA Polymerase and
dNTPs. Maxima Hot Start Taq DNA Polymerase is a Taq DNA polymerase which is
inactive at room temperature. The qPCR buffer contains KCl and (NH4)2SO4 to provide
high specificity of primer annealing.
The SYBR Green I is an intercalating dye that allows DNA detection and analysis
without using sequence-specific probes. SYBR Green I is a fluorescent intercalating dye
that emits a fluorescent signal when it binds to the double stranded DNA. The fluorescent
signal is proportional to the dsDNA concentration (Figure 3). The excitation maxima of
SYBR Green I is 494 nm and emission maxima is 521 nm. SYBR Green I is compatible
with the use of BioRad CFX96 Real-Time System.

A

B

Figure 5.3. (A) SYBR Green I structure, (B) SYBER Green I upon binding to dsDNA
emits fluorescence very brightly, (B) Signal intensities correlate with DNA amplified, thus, the
initial sample input amount.

For normalization of the SYBR Green I, ROX is used as a reference dye (Figure
5.4). It allows for correction due to pipetting imprecisions and fluorescence variations.
ROX does not participate in a PCR reaction. The excitation and emission maxima are 580
nm and 621 nm.

Figure 5.4. ROX chemical formula

After purification of the total RNA from cells, reverse transcription of RNA, realtime PCR reactions were performed for five biological replicates of four cDNA samples.
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The samples were: (1) the control sample represented by cells treated with vehicle, 0.1 %
DMSO, (2) cells treated with 0.1 µM NV1078 polyamide for 24 hours, (3) cells treated with
0.1 µM NV1042 polyamide for 24 hours, and (4) cells treated with 0.1 µM NV1011 for 24
hours. The transcription level was measured for 7 DDR target genes, ATM, ATR, RAD1,
RAD9, CHEK1, CHEK2, and TP53 (Table 5.5), and for 5 reference genes: ACTB, PGK1,
GAPD, PPIA, and RPL13A (Table 5.6).
The transcription levels of one set of biological replicates were analyzed in the
same time in the same 96-well plate (Bio-Rad) to minimize run-to-run differences, and the
same threshold setting was used for the determination of the quantification cycle values
(Cq). The raw quantification cycle values for the biological replicates are presented in
Tables 7, 9, 11, and 13.
Table 5.5. Target DDR genes used in the study
Human Gene
Ataxia Telangiectasia
Mutated
Ataxia Telangiectasia and
Rad3 Related
Rad1 Homolog

Gene Symbol

Citation

ATM

DSB Repair

(5, 6, 9) (34)

ATR

SSB Repair

(5, 6, 9)

RAD1

Rad9 Homolog

RAD9A

Chk1 Checkpoint Homolog

CHEK1

Chk2 Checkpoint Homolog

CHEK2

Tumor Protein P53

Activity/Repair

TP53

9-1-1 complex member,
exonuclease
9-1-1 complex member

(6)

DDR ATR checkpoint
effector
DDR ATM checkpoint
effector
Tumor suppressor,
transcriptional regulator

(5, 6)

(6)

(5, 6)
(6)

The reference genes (Table 5.6) should be stably expressed. The expression level
of those genes was measured simultaneously with the target genes to eliminate
experimental differences.
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Table 5.6. Reference genes level of expression and function
Human Gene

Relative
expression
level

Gene Symbol

Actin, beta

ACTB 1

+++

Phosphoglycerate kinase 1

PGK1

+++

Peptidyl prolyl isomerase A

PPIA

+++

RPL13A

+++

GAPD

+++

Ribosomal protein L13A
Glyceraldehyde-3-phosphate
dehydrogenase

Function

Cytoskeletal structural
protein
Phosphate group transfer in
glycolytic pathway
Cis-trans isomerization of
proline imidic peptide
bonds
Structural component of the
large ribosomal subunit
Oxidoreductase in
glycolysis and
gluconeogenesis

The specific primer set sequences for target genes (Table 5) as well as reference
genes (Table 6) are not disclosed by the vendor (RealTimePrimer). A possible primer
sequence can be found on the RT Primer Data Base website (RTPimer) which is a
collection of submitted primer pairs and assays used in RT-qPCR experiments.
The expression of target genes normalized to 5 reference genes and relative to a
calibrator (untreated cells) was calculated based on the Livak (ΔΔCq) method (144)
according to Minimum Information for Publication of Quantitative Real-Time PCR
Experiments (MIQE) guidelines (145).
The Livak method requires that the target and reference gene amplify at
efficiencies near 100% and have efficiencies within 5% of each other. Three steps are
required for calculations (1) normalize Cq (target gene) to Cq (reference gene) for control
samples and test samples; (2) normalize ΔCq of the test sample to ΔCq of the calibrator
(control); (3) Calculate expression ratio, or fold difference.
1. Normalize Cq of the target gene to Cq of the reference gene
ΔCq(calibrator) = ΔCq(control) = Cq (target, calibrator) - Cq (reference, calibrator)
ΔCq(calibrator) = ΔCq(control) = Cq (target, calibrator) - average Cq (ref., calibrator)
Cells treated with vehicle 0.1% DMSO are the control cells
ΔCq(test) = Cq (target, PA treated) - Cq (reference, PA treated) = ΔCq(PA)
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ΔCq(test) = Cq (target, PA treated) – average Cq (reference, PA treated) = ΔCq(PA)
2. Normalize ΔCq of test sample to ΔCq of calibrator
ΔΔCq = ΔCq(calibrator) - ΔCq (test)
3. Calculate the fold difference in expression
Normalized Expression Ratio = RQ=2ΔΔCt
The RQ values obtained in this way represent a change in the expression of the gene
of interest between the test and the calibrator conditions normalized for any differences in
loading between the reference and test samples.
5.4 Results and Discussion.

Effects of polyamides on 7 DDR gene

expression
The goal of this project was to have an initial feedback (before the analysis of
RNASeq data) on polyamide effects regarding gene expression. RT-QPCR studies
monitored expression of the seven DDR genes (Table 5.5) at the mRNA level.
Herein, the effects of three polyamides on 7 DDR gene expression compared with
the expression of the genes in the control cells is presented. Description of procedure in
a nutshell:
W12E cells were seeded in six-well plates (1X105 cells per well) over (1X105 cells
per well) mitomycin treated 3T3 cells and treated with 0.1 µM PA for 24 h. The total RNA
was extracted and purified using RNeasy Plus Mini Kit along with QIAshredder
homogenizer columns to obtain a homogenized lysate. The quality of the RNA samples
was confirmed using an Agilent 2100 Bioanalyzer with an RNA 6000 NanoKit for analysis.
The RIN values were 10 for all samples (Table 5.4). cDNA was synthesized from 1 µg of
DNA-free total RNA in a 20 µL reaction volume using a Maxima First Strand cDNA
Synthesis Kit for RT-qPCR. The obtained cDNA samples were diluted 20-fold for RT-PCR
reactions. Transcription levels for each specific gene were determined in a 20 µL reaction
volume using Maxima SYBR Green/ROX qPCR Master Mix on a CFX96 real-time PCR
machine (CFX Manager Version: 3.1.1517.0823, Bio-Rad). Gene expression was
analyzed using the relative quantification method. The relative quantification method
estimates the level of gene expression against the control. The control samples were
W12E cells treated with 0.1% DMSO, used as a vehicle for polyamides. Real-time PCR
reactions of four cDNA samples (control, samples treated with NV1078, NV1042, and
NV1011) using the same primer sets, seven DDR target (Table 5.5) and five control genes
(Table 5.6) were analyzed together in the same 96-well plate in order to use the same
threshold setting for determination of the quantification cycle values (Cq).
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Data analysis: Post PCR quality control. Gene expression had been analyzed
using the relative quantification method (RQ) named also comparative Cq method which
estimates the level of gene expression against the calibrator. In this case, the calibrator
sample is W12E cells treated just with 0.1% DMSO vehicle. Five reference genes were
used as a loading control to show that the efficiencies of the target DDR genes and control
amplification are approximately equal.
The typical use of a single gene for normalization leads to errors. Instead, the
geometric mean of multiple housekeeping genes (optimal number varies from one to more
than ten (146)) was validated as an accurate normalization factor. The expression of
reference genes used should not change in the cells under examination or in response to
experimental treatment.
In this work, the Vandesompele (147) normalization strategy was used, which
employs the calculation of a normalization factor based on three to five reference genes.
The expression stability for a particular gene is reflected by the M value calculated by the
Bio-Rad CFX Manager 3.1 software and represents the mean standard deviation of the
log-transformed expression ratios across samples for the particular gene relative to other
reference genes in the gene panel (146).
The most stable reference genes are those with the lowest CV and M value. The
recommended stability values for samples are:
(1) Mean CV value ≤ 0.25 and Mean M value ≤ 0.5 for homogeneous sample, and
(2) Mean CV value < 0.5 and Mean M value < 1 are considered acceptable for
heterogeneous samples.
The plots of fluorescence vs. cycle number are presented in the supplementary
information at the end of the chapter. The raw quantification cycle values for the biological
replicates are presented in Tables 5.7, 5.9, 5.11, 5.13, and 5.15.
Tables 5.7, 5.9, 5.11, 5.13, and 5.15 present the quantification cycle (Cq) number,
previously known as the threshold cycle (Ct). The first seven columns show the values
associated with the DDR genes mentioned in the raw above the table. The last five
columns display the Cq values related to the reference genes. The reference genes have
a high expression level compared with the DDR genes.
Figures 5.5 – 5.9, display the effects of the three different polyamides for the
biological replicates according to the normalized relative expression (RQ=2ΔΔCq) values of
the seven DDR genes to four reference genes. Although the study employed five
reference genes, just four were used in the normalization process. ATCB was not found
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to be stably expressed and was eliminated from calculations. Expression stability for a
particular gene was assessed based on the M value. The normalization aim was to use
reference genes that give a mean CV value ≤ 0.25 and a mean M value ≤ 0.5 (see Data
Analysis). The bar graphs were obtained through the use of Bio-Rad CFX Manager 3.1
software.
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Table 5.7. Cq values of qPCR experiments of C-1 Series, 1th biological replicate. C-1:
control 0.1% DMSO-1, 78-1: NV1078-1, 42-1: NV1042-1, 011-1: NV1011-1. ECF4165,
4/11/16

A

B

C

D

ATM

ATR

Content

Unk n

Unk n

Sample

C-1

Rad1

Rad9

CHEK1

Chek2

TP53

ACTB

PGK1

GAPD

PPIA

RPL
13A

Unk n

Unk n

Unk n

Unk n

Unk n

U nk n

Unk n

U nk n

Unk n

Unk n

C-1

C-1

C-1

C-1

C-1

C-1

C-1

C-1

C-1

C-1

C-1

Cq

23.61

21.82

21.67

23.38

20.20

22.88

20.98

16.83

18.98

15.13

15.32

17.49

Content

Unk n

Unk n

Unk n

Unk n

Unk n

Unk n

Unk n

U nk n

Unk n

U nk n

Unk n

Unk n

Sample

78-1

78-1

78-1

78-1

78-1

78-1

78-1

78-1

78-1

78-1

78-1

78-1

Cq

23.34

21.42

21.40

23.20

19.87

22.39

20.73

15.43

18.59

14.55

14.77

16.10

Content

Unk n

Unk n

Unk n

Unk n

Unk n

Unk n

Unk n

U nk n

Unk n

U nk n

Unk n

Unk n

Sample

42-1

42-1

42-1

42-1

42-1

42-1

42-1

42-1

42-1

42-1

42-1

42-1

Cq

24.01

21.82

21.72

23.41

20.48

22.92

20.83

15.91

19.06

14.78

15.05

16.45

Content

Unk n

Unk n

Unk n

Unk n

Unk n

Unk n

Unk n

U nk n

Unk n

U nk n

Unk n

Unk n

Sample

011-1

011-1

011-1

011-1

011-1

011-1

011-1

011-1

011-1

011-1

011-1

011-1

Cq

23.01

20.95

20.71

22.84

19.32

21.65

19.93

15.05

18.07

13.74

14.16

15.30

Figure 5.5. Downregulation of DDR genes in cells treated with polyamides. C-1 Series,
1th biological replicate Relative normalized expression (RQ) associated with Table 7
Table 5.8. Reference genes stability values associated with qPCR experiments of C-1
Series
C-1
Reference gene
Coeficient variance M value
1

PGK1

0.1675

0.3140

2

GAPD

0.0441

0.2375

3

PPIA

0.0758

0.2345

4

RPL13A

0.2152

0.4699

Mean value

0.13

0.31

86

Table 5.9. Cq values of qPCR experiments of C-2 Series, 2th biological replicate. C-2:
control 0.1 % DMSO-2, 78-2: NV1078-2, 42-2: NV1042-2, 011-2: NV1011-2. ECF4157,
4/4/16

A

B

C

D

ATM

ATR

Rad1

Rad9

Chk1

Chk2

TP53

Content

Unk n

Unk n

U nk n

U nk n

U nk n

Unk n

Unk n

Sample

C-2

C-2

C-2

C-2

C-2

C-2

Cq
Content

23.56

21.91

22.51

24.16

20.87

Unk n

Unk n

U nk n

U nk n

U nk n

ACTB

PGK1

GAPD

PPIA

RPL
13A

Unk n

Unk n

Unk n

U nk n

U nk n

C-2

C-2

C-2

C-2

C-2

C-2

23.16

21.08

17.86

21.29

16.96

15.98

18.69

Unk n

Unk n

Unk n

Unk n

Unk n

U nk n

U nk n

Sample

78-2

78-2

78-2

78-2

78-2

78-2

78-2

78-2

78-2

78-2

78-2

78-2

Cq

23.18

21.29

21.48

23.36

19.77

22.78

20.26

16.44

19.17

15.26

15.32

17.19

Content

Unk n

Unk n

U nk n

U nk n

U nk n

Unk n

Unk n

Unk n

Unk n

Unk n

U nk n

U nk n

Sample

42-2

42-2

42-2

42-2

42-2

42-2

42-2

42-2

42-2

42-2

42-2

42-2

Cq

22.53

21.08

21.39

23.16

20.14

22.46

20.40

16.77

19.05

15.07

14.95

17.01

Content

Unk n

Unk n

U nk n

U nk n

U nk n

Unk n

Unk n

Unk n

Unk n

Unk n

U nk n

U nk n

Sample

011-2

011-2

011-2

011-2

011-2

011-2

011-2

011-2

011-2

011-2

011-2

011-2

Cq

22.11

20.65

20.86

22.58

19.58

22.01

19.98

16.26

18.62

14.29

14.61

16.60

Figure 5.6. Downregulation of DDR genes in cells treated with polyamides. C-2 Series,
2th biological replicate. Relative normalized expression (RQ) associated with Table 9.
Table 5.10. Reference genes stability values associated with qPCR experiments of C-2
Series
C-2
Reference gene
Coeficient variance M value
1

PGK1

0.1775

0.3973

2

GAPD

0.1367

0.3430

3

PPIA

0.3088

0.5395

4

RPL13A

0.0350

0.3046

Mean value

0.1645

0.3046
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Table 5.11. Cq values of qPCR experiments of C-3 Series, 3th biological replicate. C-3:
control 0.1 % DMSO-3, 78-3: NV1078-3, 42-3: NV1042-3, 011-3: NV1011-3. ECF4148,
3/31/16

A

B

C

D

ATM

ATR

Content

U nk n

Unk n

Sample

C-3

Cq

Rad1

Rad9

CHEK
1

CHEK2

PT53

ACTB

PGK1

GAPD

PPIA

RPL
13A

Unk n

Unk n

Unk n

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

Unk n

C-3

C-3

C-3

C-3

C-3

C-3

C-3

C-3

C-3

C-3

C-3

21.55

20.20

20.20

22.18

18.59

21.22

19.14

17.58

20.38

14.63

14.54

18.28

Content

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

Unk n

Sample

78-3

78-3

78-3

78-3

78-3

78-3

78-3

78-3

78-3

78-3

78-3

78-3

Cq

21.90

19.45

19.93

21.19

18.53

20.55

18.60

13.82

17.59

13.21

13.60

15.78

Content

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

Unk n

Sample

42-3

42-3

42-3

42-3

42-3

42-3

42-3

42-3

42-3

42-3

42-3

42-3

Cq

21.77

19.79

20.30

21.66

18.73

21.17

18.83

14.14

18.05

13.38

13.50

16.30

Content

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

Unk n

Sample

011-3

011-3

011-3

011-3

011-3

011-3

011-3

011-3

011-3

011-3

011-3

011-3

Cq

21.15

19.19

19.48

21.19

18.07

20.08

18.16

13.63

17.35

12.42

13.21

15.51

Figure 5.7. Bar chart showing downregulation of DDR genes in cells treated with
polyamides. C-3 Series, 3th biological replicate. Relative normalized expression (RQ)
associated with Table 11.
Table 5.12. Reference genes stability values associated with qPCR experiments of C-3
Series
C-3
Reference gene
Coeficient variance M value
1

PGK1

0.2379

0.5294

2

GAPD

0.1598

0.4743

3

PPIA

0.3525

0.6079

4

RPL13A

0.1648

0.4384

Mean value

0.2288

0.5217

88

Table 5.13. Cq values of qPCR experiments of C-4 Series, 4th biological replicate. C-4:
control 0.1 % DMSO-4, 78-4: NV1078-4, 42-4: NV1042-4. ECF4177, 5/26/16
ATM

A

B

C

ATR

Rad1

Rad9

CHEK1

Chke2

TP53

ACTB

PGK1

GAPD

PPIA

RPL
13A

Content

U nk n

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

U nk n

Unk n

Unk n

Unk n

U nk n

Sample

C-4

C-4

C-4

C-4

C-4

C-4

C-4

C-4

C-4

C-4

C-4

C-4

Cq

23.51

22.12

22.33

24.71

23.10

23.86

21.22

14.91

21.55

16.32

16.25

18.74

Content

U nk n

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

U nk n

Unk n

Unk n

Unk n

U nk n

Sample

78-4

78-4

78-4

78-4

78-4

78-4

78-4

78-4

78-4

78-4

78-4

78-4

Cq

24.17

22.23

22.74

25.19

23.34

23.75

21.66

13.44

21.00

16.29

16.66

18.77

Content

U nk n

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

U nk n

Unk n

Unk n

Unk n

U nk n

Sample

42-4

42-4

42-4

42-4

42-4

42-4

42-4

42-4

42-4

42-4

42-4

42-4

Cq

23.52

22.04

22.11

24.85

22.98

23.01

21.13

13.73

20.26

16.37

15.69

18.12

Figure 5.8. Bar chart showing downregulation of DDR genes in cells treated with
polyamides. C-3 Series, 3th biological replicate. Relative normalized expression (RQ)
associated with Table 13

Table 5.14. Reference genes stability values associated with qPCR experiments of C-4
Series
C-4

Reference gene

Coeficient variance

M value

1
2
3
4

PGK1
GAPD
PPIA
RPL13A

0.2317
0.2390
0.1609
0.0326

0.5139
0.5364
0.4096
0.3243

Mean value

0.1660

0.4460
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Table 5.15. Cq values of qPCR experiments of C-5 Series, 5th biological replicate. C-5:
control 0.1 % DMSO-5, 78-5: NV1078-5, 42-5: NV1042-5, 011-5: NV1011-5. ECF4170,
4/22/16
ATM

Content
A

B

C

D

U nk n

ATR

Rad1

Rad9

Chke1

Chke2

TP53

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

ACTB

U nk n

PGK1

Unk n

GAPD

Unk n

PPIA

RPL
13A

Unk n

U nk n

Sample

C-5

C-5

C-5

C-5

C-5

C-5

C-5

C-5

C-5

C-5

C-5

C-5

Cq

23.92

22.12

22.20

24.42

22.49

23.12

21.08

14.56

19.08

15.45

15.76

17.54

Content

U nk n

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

U nk n

Unk n

Unk n

Unk n

U nk n

Sample

78-5

78-5

78-5

78-5

78-5

78-5

78-5

78-5

78-5

78-5

78-5

78-5

Cq

23.95

22.09

22.06

24.65

22.82

23.37

21.39

14.72

19.27

15.58

15.89

17.37

Content

U nk n

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

U nk n

Unk n

Unk n

Unk n

U nk n

Sample

42-5

42-5

42-5

42-5

42-5

42-5

42-5

42-5

42-5

42-5

42-5

42-5

Cq

24.02

22.41

22.39

24.91

23.00

23.42

21.73

14.81

19.25

15.94

14.48

17.65

Content

U nk n

U nk n

Unk n

Unk n

Unk n

Unk n

U nk n

U nk n

Unk n

Unk n

Unk n

U nk n

Sample

011-5

011-5

011-5

011-5

011-5

011-5

011-5

011-5

011-5

011-5

011-5

011-5

Cq

24.44

22.58

22.66

25.39

23.38

23.77

21.67

15.12

19.65

15.91

16.26

18.10

Figure 5.9. Bar-chart showing downregulation of DDR genes in cells treated with
polyamides. C-5 Series, 5th biological replicate. Relative normalized expression (RQ)
associated with Table 15
Table 5.16. Reference genes stability values associated with qPCR experiments
of C-5 Series
Reference gene
Coeficient variance M value
1

ACTB

0.0259

0.1165

2

PGK1

0.0573

0.1377

3

GAPD

0.0904

0.1911

4

RPL13A

0.0866

0.1817

Mean value

0.0650

0.1567

90

The selected genes’ expression was altered in all five biological replicates. Series
1, 2, and 3 presented the same trend in gene regulation. All genes were downregulated.
The similarities between the effects induced by the two active polyamides and the effect
induced by the NV1011 polyamide were unexpected. It was thought that the small NV1011
polyamide (Table 2) was inactive, and therefore will not have any effect on the cells.
All samples have been treated with 0.1 µM polyamide. Table 5.17 illustrates the
relationship between the IC50 and IC90 values (Chapter 1) and the experimental
concentration.
Table 5.17. The IC50 and IC90 values and their relationships to 0.1 µM concentration
Polyamide
IC50 (µM)
IC90 (µM)
0.1µM/IC50
0.1µM/IC90
NV1078
0.046
0.307
2.2
0.3
NV1042
0.036
0.351
2.8
0.3

The polyamide concentration used for the treatment of the cells was 2.8 times higher
than the IC50 of the NV1042 polyamide, and 2.2 times greater than the IC50 of NV1078,
determined in the same conditions. Consequently, when interpreting the changes in the
level of expression for the same gene, this difference has to be taken into consideration.
ΔΔCq was calculated for each target gene against the average of four control
genes. For the first three samples, this method produced 9 pair-wise comparisons for each
gene (3 DMSO treated ΔCq values x 3 PA treated ΔCq values) (6). The genes are
considered affected by polyamide treatment if at least 2 fold (|ΔΔCq| ≥ 1) or more change
was registered in their expression compared with the same gene expression in samples
treated with 0.1% DMSO (control) (6). The value ΔΔCq = 1, accounts for RQ = 2 ΔΔCq = 2,
two-fold change, and is therefore considerate to be significant (Table 5.19 and Figure
5.10).
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Figure 5.10 Gene expression downregulation induced by NV1078, NV1042 and
NV1011. All 9 ΔΔCq values are shown as well as the median line and the average (x)
values for every gene.
92

Taking into consideration that the ATM pathway activated by double-stranded
breaks and the ATR pathway activated by single-stranded breaks are linked to each other
as demonstrated by recent studies reviewed by Hong and Laimins (15) it makes sense to
have the same trend for ATM/CHEK2 and ATR/CHEK1 pairs. ATR seems to be
subordinated to elements of ATM. The ATR–CHK1 pathway requires activation by ATM.
(15).
In our case, the regulation of ATM was also correlated with the regulation of
downstream element P53. In the same way, the regulation of ATR was associated with
the expression levels of Rad9, Rad1, and P53. Their expression was also downregulated.
We already know that the large polyamide NV1042 induces a DDR response in
the cells infected with the HPV16 virus (5, 6, 117). We also know from the same study
that ATM is important for episome maintenance (6) because the siRNA-mediated
knockdown of the gene drastically decreased the episome numbers in W12E cells.
It was also demonstrated that the significant viral loss registered when infected
cells were treated with the same NV1042 active polyamide is a consequence of the
degradation of the viral episome, not just the inhibition of viral DNA replication (117).
Therefore, it may be postulated that the downregulation of the DDR elements registered
in samples treated with NV1042 and NV1078 polyamides is a direct consequence of the
episome degradation. The present results reinforce the principle that the episome
degradation was accomplished by the polyamide treatment.
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Table 5.18. Comparison of gene expression altered by NV1042 (PA25) in W12E cells,
induced in two different conditions. W12E cells were incubated with 10µM NV1042 for 48
hours (6), and this work, W12E cells were incubated with 0.1µM NV1042 for 24 hours
(biological replicate #3), Fold Δ: 2 ΔΔCq

Human Gene

mRNA (Fold

mRNA (Fold Δ)

Function/Pathway

Δ)(6)

Ataxia Telangiectasia

-3.68

-3.5 (2 1.8 )

PI-3 kinase

Mutated, ATM
Ataxia Telangiectasia

HR, DSB Repair,

…

-2.3 (2 1.2 )

HR, SSB Repair

-67.65

-3.3 (2 1.7 )

9-1-1 member,

and Rad3 Related, ATR
Rad1 Homolog, RAD1

exonuclease
Rad9 Homolog, RAD9A

….

-2.1 (2 1.1 )

9-1-1 complex
member

Chk1 Checkpoint

-4.17

-3.3 (2

1.7 )

DDR ATR
checkpoint
effector

-2.62

-3.0 (2 1.6 )

DDR ATM
checkpoint
effector

….

-2.5 (2 1.3 )

Tumor
suppressor,
transcriptional
regulator

Homolog, CHEK1
Chk2 Checkpoint
Homolog, CHEK2

Tumor Protein P53,
TP53
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Table 5.19. Nine pair-wise (3 DMSO treated ΔCq values x 3 PA treated ΔCq
values) comparisons.

GENES
ATM
ATR
RAD1
RAD9A
CHEK1
CHEK2
TP53

downregulated
upregulated
downregulated
upregulated
downregulated
upregulated
downregulated
upregulated
downregulated
upregulated
downregulated
upregulated
downregulated
upregulated

NV1011
ΔΔCt≥1
7/9
5
2/9
0
7/9
6
2/9
0
7/9
4
2/9
0
7/9
4
2/9
0
8/9
5
1/9
0
7/9
5
2/9
0
7/9
5
2/9
0
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NV1042
ΔΔCt≥1
7/9
5
2/9
0
7/9
5
2/9
0
8/9
4
1/9
0
7/9
4
1/9
0
7/9
5
1/9
0
7/9
6
2/9
0
7/9
5
2/9
0

NV1078
ΔΔCt≥1
7/9
6
2/9
0
7/9
5
2/9
0
7/9
4
2/9
0
7/9
4
1/9
0
8/9
4
1/9
0
7/9
5
2/9
0
7/9
4
2/9
0

5.5 Annotations
HR: Homologous recombination, exchange of base-paired partners between two
homologous DNA molecules (113)
CHEK1,2: checkpoints, places in the cell cycle where DNA sequence and structure
fidelity are ascertained before progression to the subsequent phase of the cell
cycle (113)
STAT5: Signal transducer and activator of transcription
qPCR: quantitative real-time PCR (145)
RT-qPCR: reverse transcription quantitative real-time PCR (145)
Reference genes: previously known as housekeeping or control genes (145)
Quantification cycle Cq: previously known as the threshold cycle (Ct), the cycle
at which fluorescence from amplification exceeds the background fluorescence
(145)
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5.6 Supplementary Information

Figure S1. Electropherograms of extracted RNA; quality and integrity of the RNA were
measured using the Agilent Bioanalyzer 2100, yielding RIN scores of 10.
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Chapter 6
The Analysis of Viral and Human Transcriptomes After Treatment of W12E Cells
with Polyamides
6.1 Introduction
Based on the knowledge gathered from the results of the binding studies in
Chapters 3 and 4 and those reported recently (11, 105), coupled with the first gene
expression array work on a limited but important set of mRNA levels (6), a complex study
concerned with genome-wide expression was designed. With the help of high-throughput
sequencing (HiSeq techniques) host and viral mRNA expression will reveal any genes
regulated by the polyamides. Thus, the aim of this gene expression project is to find the
similarities and differences in different polyamides’ mechanism of action related to gene
expression by quantifying messenger RNA (mRNA) after treatment of HPV-infected
keratinocyte (W12E) cells separately with eight polyamides (Table 6.1). The viral
transcriptome data obtained after the treatment of cells with polyamides will be compared
with the known viral transcriptomes (148, 149) and to each other. By comparing samples
treated with different polyamides, different expression levels and different splicing sites
may be revealed (150).
The HPV mRNA is polycistonic in both the episomal form and when integrated into
human chromosomes (21, 148-150). In undifferentiated cells, the transcription is initiated
by the early promoter (p97) and is terminated at the early poly(A) signal, AE, while the
mRNA encoding the viral early genes is produced. In differentiated cells, the transcripts
are expressed by the late promoter (p670) and utilize a late poly(A) signal, AL, while they
produce mRNA for the late genes (45). The transcripts in this situation are terminated at
the late poly(A) signal (Figure 6.1) (46). By checking the level of E6 and the late L1 and
L2 genes, it is possible to assess the replication phase of the virus.
The human transcriptome data obtained after sequencing results are fullyprocessed will aid in understanding how polyamides help infected cells eliminate the
virus from a genomic perspective.
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Figure 6.1. The HPV genome circular dsDNA structure (46)
6.2 Materials and Methods
A detailed description of the cell culture (5.3.1), polyamide treatment (5.3.2), and
RNA extraction (5.3.3) methods is provided in Chapter 5.
For the RNASeq experiment, an inactive polyamide (NV1011) and 7 active
polyamides were used. Among the active polyamides are the two, PA1 and PA42, leading
compounds of the HPV viral research. Three TMG compounds NV1078, NV1087 and
NV1113, and two guan compounds NV1111 and NV1115 (Chapter 1, Table 1.2) were
chosen because of their excellent potency in cell cultures harboring HPV 16 or HPV 18.
Table 6.1. Polyamides used for RNASeq studies. The IC50 and IC90 values
measured in W12E cells were determined by T. G. Edwards in the Fisher lab (unpublished
data).
PA

HPV16 IC50 [µM]

HPV16 IC90 [µM]

HPV18 IC50 [µM]

HPV18 IC90 [µM]

NV1011 (PA11)
NV1028 (PA1)
NV1042 (PA25)
NV1078

NOT ACTIVE
0.100
0.036
0.046

NOT ACTIVE
1.113
0.351
0.307

NOT ACTIVE
0.717
0.056
0.030

NOT ACTIVE
>10
1.462
0.091

NV1087
NV1111
NV1113
NV1115

0.031
0.017
0.304
0.103

0.200
0.121
>10
0.378

0.024
0.018
0.228
0.167

0.297
0.136
>10
0.937

6.2.1 TruSeq Stranded mRNA Library Preparation
All total RNA samples used for library preparation were of excellent quality
(RIN=10, see Chapter 5) and high concentration (Table 5.4 and Figure S1 in Chapter
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5), and had fallen into the range recommended by ILLUMINA for sequencing is (0.1 - 4)
µg/mL.
The total RNA (tRNA, not meaning transfer RNA in this context) samples stored at
-800C

were used for preparing the NextGen sequencing libraries according to TruSeq

Stranded mRNA Library LS Prep protocol for 45 samples using 9 adapters (Illumina,
RS122-2102 set B Kit). The adapter includes the index, a unique sequence of 6
nucleotides. The index is used to identify the sample. Different input quantities, ranging
from 500 to 1000 ng of total RNA, were used to allow the determination of the ideal amount
for preparing a complementary ds DNA library with the selected method. The best library
quality was obtained using lower tRNA quantities (Table 6.3). Therefore, the majority of
libraries were prepared from 500 ng total RNA as starting material.
The tRNA samples were subjected to a series of steps to obtain ds cDNA ready
for sequencing. The first step was the purification of messenger RNA (mRNA) from total
RNA and its subsequent fragmentation. In this way, non-polyA RNA, or ribosomal RNA,
was separated from the pool of interest. PolyA mRNA was purified using polyT-oligoattached magnetic beads provided with the Illumina kit. Two rounds of elution were
performed. During the first round of purification, the mRNA was denatured and bonded to
the PolyT sequences attached to the beads. During the second purification, mRNA was
fragmented into small pieces with a median size of 150 bp, using divalent cations under
elevated temperature. The purified and fragmented mRNA was primed with random
primers for cDNA synthesis.
The purified and fragmented mRNA was primed with random primers for cDNA
synthesis in the presence of reverse transcriptase SuperScript II. This process reverse
transcribed the cleaved RNA fragments primed with random hexamers into first strand of
cDNA. Actinomycin improved the specificity of the process, allowing RNA-dependent
synthesis. For the interpretation of the RNA-seq results only the first cDNA strand, which
is the anti-sense strand, is sequenced. During the process of the second strand cDNA
synthesis, the template mRNA was removed, and the complementary strand generated
the final ds cDNA.
Agencourt PAMPure XP beads, which selectively bind DNA sequences longer than
100 bp, were used to capture the ds cDNA from the second strand reaction mix. To the
generated, blunt-ended, ds cDNA, a single “A” was added to the 3’ ends to which a
corresponding single “T” at 3’ end of the adapter makes available a complementary
overhang for ligating the adapter to the fragment.
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Different y-shaped indexing adapters were ligated to the ends of different ds cDNA
samples (Table 6.2) with the use of T4 DNA ligase. The adapters contain the (1)
sequencing primers, (2) the index sequence and (3) oligonucleotides complementary to
the sequencing machine’s flowcell DNA sequences. Thus, the adapters hybridize with the
flowcell oligos.
Table 6.2. Adapters associated with different samples
Sample (1-9)
NV1078
NV1087
NV1042
NV1028
NV1111
Control 0.1% DMSO
NV1011
NV1113
NV1115

Adapter
AR001
AR003
AR008
AR009
AR010
AR011
AR020
AR022
AR025

Index Sequence
ATCACG(A)
TTAGGC(A)
ACTTGA(A)
GATCAG(A)
TAGCTT(A)
GGCTAC(A)
GTGGCC(T)
CGTACG(T)
ACTGAT(A)

To increase the amount of ds cDNA, enrichment with PCR was performed with a
Primer Cocktail that anneals just to the ends of the adapters. In this way, just ds DNAs
that have adapters ligated to the both ends will be amplified. After a new purification with
AMPure XP beads the quantity and the quality of libraries were evaluated.
6.2.2 NextGen Library Quality Control. Validation and Quantification of
TruSeq library
The size distribution after fragmentation of ds cDNA and adapter ligation was
assessed on a BioAnalyzer Agilent 2100 instrument according to the Agilent DNA 1000
Kit (5067-1504) protocol. The results are presented in Table 6.2. In addition, a Qubit 2.0
Fluorometer was employed to determine the concentration of the TruSeq library with the
help of Qubit dsDNA BR Assay Kit, catalog no. Q32850. The molar concentration of the
samples was estimated by averaging the concentrations of both Qubit and BioAnalyzer
measurements. The molar concentration was double-checked with a Qubit 3.0
Fluorometer at DNA Core Facility, University of Missouri, Colombia. 10 nM stock libraries
were used to prepare DNA templates for cluster generation.
6.2.3 Sequencing and Alignment
The subsequent work, pooling of the libraries and sequencing on HiSeq 2500
Illumina instrument, was performed by Nathan Bivens and his colleagues at the DNA Core
Facility, University of Missouri, Colombia. The sequencing results’ interpretation is being
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performed at Informatics Research Core Facility (IRCF) by Christopher Bottoms under the
supervision of Dr. Scott Givan
The latent Illumina adapter sequences were identified and removed from the RNASeq data using bcl2fastq version 2.17.1.14 (run with command-line parameters "-minimum-trimmed-read-length=10 --mask-short-adapter-reads=9"). Subsequently, input
RNA-Seq data was trimmed and filtered to remove low quality nucleotide calls and whole
reads, respectively, using the Fastx-Toolkit, version 0.0.13. From the remaining RNA-Seq
data, foreign or undesirable reads were removed by sequence matching to filter
sequences, using Bowtie, version 0.12.9. Filter sequences included the following (National
Center for Biotechnology Informatics accessions in parentheses): Phi-X genome
sequence (NC_001422.1), the pUC19 vector (M77789.2), human ribosomal RNA
sequences, the human mitochondrial genome (from Genomic Reference Consortium
assembly h38), an additional human mitochondrial sequence (NCBI accession S64650.1),
and Human genomic repeat elements in RepBase, version 20.02. The remaining RNASeq data was subjected to genome alignment, transcript assembly and expression
quantification

using

TopHat,

version

2.1.0,

via

the

RNA-Seq-Toolkit

(https://github.com/sgivan/RNA-Seq-Toolkit, (151) The differential expression analysis
was done using Cufflinks and Cuffdiff, version 2.2.1. Computational hardware used
included the BioCluster of the Informatics Research Core Facility (University of Missouri)
and the Lewis Cluster of Research Computing Support Services (University of Missouri).
Just unique reads-anti-sense expression of the transcripts is being used since the
library was prepared using a strand specific preparation kit that only sequenced the
first cDNA strand.
Analysis of the summary file will lead to the discovery of transcripts that are
statistically differentially expressed in these data.
6.3 Partial Results
The size distribution of the TruSeq stranded mRNA libraries after adapter ligation
shows ideal distribution, 260 bp, as can be seen in the profiles generated by Agilent 2100
Bioanalyzer (Supplementary Figures). The molar concentration of the 45 libraries is
presented in Table 6.3.
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Table 6.3. TruSeq Stranded mRNA Libraries characteristics. The table includes the amount of total
RNA used for library preparation, and the average size and the concentration of ds DNA,
determined with BioAnalyzer Agilent 2100. The molar concentration was calculated with
ScienceLauncher software http://www.sciencelauncher.com/mwcalc.

Sample

RNA Amount
(ng)

BioA
dsDNA
(ng/μL)

BioA
[DNA]
(nM)

dsDNA
Average
Size (bp)

NV1078-1

628

18.75

88.35

327

NV1028-3
0.1%DMSO-1

500
1000

24.83
20.27

125
98.2

306
317

NV1087-1

500

11.67

57.63

312

NV1042-1
NV1028-1

500
500

20.92
13.46

105.69
69.6

305
298

NV1111-1

500

22.79

118.23

297

NV1042-2
NV1078-2

500
738

14.64
20.27

78.33
104.11

288
300

NV1087-2
NV1028-2

690
944

18.6
24.06

97.48
127.4

294
291

NV1111-2

670

28.23

152

286

0.1%DMSO-2
NV1078-3

542
500

15.41
22.37

81.32
115.67

292
298

NV1087-3

500

18.86

97.85

297

NV1111-3
0.1%DMSO-3

500
500

24.62
17.48

127.73
94.84

297
284

NV1042-3

500

17.67

92.29

295

NV1011-1
NV1113-1

500
500

14.25
15.04

73.68
74.76

298
310

NV1115-1

500

7.04

38.6

281

NV1011-2
NV1113-2

500
500

15.14
15.16

75.99
76.09

307
307

NV1115-2

500

13.52

71.73

284

NV1011-3
NV1113-3

500
500

19.74
20.67

108.24
103.74

281
307

NV1115-3

500

43.68

213.66

315

NV1078-4
NV1087-4

500
500

22.47
23.93

116.57
119.33

297
309

NV1042-4

500

17.16

86.41

306

NV1028-4
NV1111-4

500
500

17.71
29.77

91.88
150.89

297
304

0.1%DMSO-4

500

24.59

127.14

298

NV1011-4
NV1113-4

500
500

19.55
23.3

99.42
116.19

303
309

NV1115-4

500

27.05

137.56

303
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Sample
NV1078-5

RNA Amount
(ng)
500

BioA
dsDNA
(ng/μL)
19.89

BioA
[DNA]
(nM)
102.16

dsDNA
Average
Size (bp)
302

NV1087-5

500

22.09

113.46

301

NV1042-5
NV1028-5

500
500

18.51
35.52

97
186.8

294
293

NV1111-5

500

31.02

159.32

300

0.1%DMSO-5
NV1011-5

500
500

35.9
17.27

180.18
85.29

307
312

NV1113-5

500

20.67

108.7

293

NV1115-5

500

22.88

111.92

315

The nine samples (a biological replicate series) were multiplexed per lane, and
every set of sample was run in three lanes to obtain a statistically relevant amount of reads
(50M). The possibility of pooling the maximum of 9 samples together in one lane was
verified prior to library preparation with Illumina Experiment Manager (IEM) software.
The sequencing runs were of high quality Q30 score was over 90%, % PF clusters
over 90, and the perfect barcode over 99% for every sample (Flowcell Summary and Lane
Summary ECF4172-4175).
6.4 Overall conclusions
To treat current or future HPV infections, drugs that selectively block virus-specific
processes, but do not damage the host cells, are needed. The compounds developed in
Dr. Bashkin’s lab are unique imidazole-pyrrole polyamides which have anti-HPV activity.
Biophysical studies of two TMG asymmetric hairpin polyamides (NV1078 and
NV1087) on HPV LCR segment revealed that although the polyamides bind in many
different sites, they have a noticeable preference for the region adjacent and overlapping
with the E1, E2 binding sites (Figure 4.11). The intensive binding in the minor groove of
dsDNA (sequence 7880-30 of HPV16 and sequence 7841-43 of HPV18) of TMG-AHPs
structurally alter the dsDNA. The required adjustments of the DNA to allow binding may
cause the inability of E1/E2 to assemble, as a replication competent double-hexamer at
the ORI, obstructing the replication process at the start. The intensive binding in the region
mentioned above may also cause ssDNA exposure or double strand breaks within HPV
DNA and the activation of DNA damage response pathways (6). Multiple binding sites
induce DNA nicks which activates ATR and ATM.
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The partial results of gene expression analysis exposed genes that are relevant to
the polyamide mechanism of action. After treatment of W12E cells with active polyamides
a downregulation of ss and ds signal transducers ATM and ATR was registered. The
regulation of ATM was also correlated with the regulation of downstream element TP53.
In the same way, the regulation of ATR was associated with the expression levels of Rad9,
Rad1, and P53. Their expression was also downregulated. The downregulation of the
DDR elements registered in samples treated with NV1042 and NV1078 polyamides is a
direct consequence of the episome degradation. The present results reinforce the principle
that the episome degradation was accomplished by the polyamide treatment.
Our findings complement the notion that the PA binding to negatively supercoiled
HPV episomes activate the DNA damage response (DDR) pathways (6). Activation of
DDR genes eliminates the viral episomes without having substantial effects on cell growth
or apoptosis (6).
The elimination of viral DNA during the maintenance stage it is an effective strategy
for the development of antiviral compounds. The large Im-Py polyamides synthetized in
the Bashkin’s lab have the potential to be useful for the treatment of preexisting and future
HPV infections.
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6.5 Supplementary Material.S1
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